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 ABSTRACT 
 
 Although many researchers have examined the effects of electroconvulsive 
therapy (ECT) on memory and cognition, few investigators have studied the 
neurocognitive effects of bifrontal electrode placement in ECT treatment. The 
current study was designed to examine the clinical efficacy and neurocognitive 
effects of bifrontal ECT. Participants included 17 adults between the ages of 23 
and 62 years of age, all of whom had been diagnosed with unipolar or bipolar 
depression and met hospital criteria for ECT treatment, that is, had failed other 
treatment efforts. Recruitment of participants took place between 2009 and 2010 
at a university-based psychiatric hospital. Following consent to participate and 
assurance that recruits met study criteria, a psychiatric interview was conducted 
and psychological/neuropsychological tests were administered. The tests were 
selected for the purpose of quantifying depressive symptoms and cognitive skills 
thought to be affected by ECT (anterograde and retrograde memory, executive 
functions, and processing speed). 
 Results of the study demonstrated that bifrontal ECT can be an effective 
treatment of depression in that 88% of participants showed reduced depressive 
symptoms immediately after ECT treatment and 77% of these initial remitters 
continued to show response to treatment 1 month later. Although data also 
    
iv 
showed that the participants had posttreatment problems with retrograde 
amnesia which had not resolved by follow-up 1 month later, and had impaired 
verbal fluency immediately posttreatment which remitted by follow-up, there 
were no indications that the ECT treatment caused anterograde memory 
problems or other nonmemory cognitive problems. Specifically data showed no ill 
effects of bifrontal ECT on processing speed and executive functions (inhibition, 
motor planning and response, sequencing, and cognitive flexibility). Without a 
control group or randomized assignment to treatment, no firm conclusions can 
be drawn from the current findings; however, the findings are important in that 
they suggest that bifrontal ECT treatment is as effective in addressing treatment-
resistant depression as other ECT methods which entail electrode placements 
that may produce greater and more persistent cognitive side effects, including 
bitemporal ECT.
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Each year depression torments approximately 15 million adults, roughly 
7% of the U.S. population (Kessler, Chiu, Demler, & Walters, 2005). Treatment 
for depression typically begins with psychotherapy and medication.  However, 
psychopharmacological intervention appears ineffective for one-third to half of 
those suffering from severe depression (Rush et al., 2006). Furthermore, 
medications can have intolerable side effects including metabolic syndrome and 
increased risk for suicide. A recent large scale trial (commonly called the STAR*D 
trial) investigating four levels of psychopharmacological treatment for severe 
depression found that 67% of participants responded to medication across the 
four levels, with remission rates between 20 and 30% depending on the 
medication prescribed (Rush et al., 2006). These figures suggest that 
approximately one-third of people treated with antidepressant medications may 
not respond favorably even after several alternative medications are attempted. 
Another problem associated with medication is poor treatment adherence, which 
further complicates estimates of individual response to medication. 
 For patients with pharmacological-resistant depressive conditions 
electroconvulsive therapy (ECT) is the most effective treatment (UK ECT Review 
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Group, 2003; Kho, van Vreeswijk, Simpson, & Zwinderman, 2003). Two multisite 
collaborations (Consortium for Research in ECT, 2001 and Columbia University 
Consortium, 2006) found remission rates between 55% (Sackeim et al., 2001) 
and 64% (Kellner et al., 2006) for ECT which compare favorably to the initial 
30% remission rate with citalopram, as well as remission rates of 23% with 
bupropion, 21% with sertraline, and 25% with venlafaxine for patients in the 
STAR*D trial who did not initially respond to citalopram (Rush et al., 2006). 
These data strongly support the superior clinical efficacy of ECT over 
psychopharmacological approaches for treatment-resistant depression. 
ECT involves the application of electrodes to the head. Through those 
electrodes, electrical charges are delivered to induce convulsion. Currently, ECT is 
administered to over 100,000 patients per year in the U.S. (Hermann, Dorwart, 
Hoover, & Brody, 1995), and an estimated 1 million patients per year outside the 
U. S. (Prudic, Olfson, & Sackeim, 2001). However, considering that medications 
are ineffective for at least 30% of people suffering from depression, about 3 
million patients per year are left without some type of treatment, including those 
who might be potentially beneficial in reducing their symptoms.  
 
Efficacy, Use, and Perception of ECT 
Despite its clinical efficacy, ECT is underutilized. In a commentary on ECT 
published in the Journal of the American Medical Association in 2007, Fink and 
Taylor suggested several hypotheses accounting for the underuse of ECT in the 
U.S. One such factor contributing to ECT’s underuse is that medical schools lack 
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preparation and education emphasizing ECT as a viable treatment option, as it is 
not a required subject of study in U.S. medical schools.  Further, despite clear 
research support ECT is not a required competency domain in psychiatric 
residency training. Additionally, there is little formal regulation of ECT practice in 
the U.S. 
 Another barrier to ECT's widespread application is that U.S. approved 
devices have a limited energy range. In some cases, this limitation may prevent 
patients from being treated at the seizure thresholds required for effective 
treatment. This is a problem, especially for older patients, many of whom 
demonstrate higher seizure thresholds. Devices approved for use in Canada and 
Europe can deliver twice the energy of approved U.S. instruments, presumably 
improving treatment outcomes. Finally, Fink and Taylor (2007) point out that, 
despite well-documented efficacy and safety, ECT continues to be stigmatized 
and is primarily employed as a last-resort treatment option.  
 The poor image of ECT in both public and professional opinion revolves 
around the presumed effects of ECT on memory and other cognitive functions. 
Even though most research in this area suggests that any adverse effects are 
mild and short in duration, the opposite perception continues to be the primary 
barrier to broad application of ECT. In fact, the social stigma accompanying 
memory impairment and the fears associated with induced grand mal seizures 
likely lead many patients to decline ECT treatment each year.  Unfortunately, this 
number has not been quantified in the research.  
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 In an investigation of patient opinion about ECT, Malcolm (1989) 
interviewed 100 patients who were due to receive ECT. He found that 
approximately 60% feared the procedure. Specifically, patients were afraid of 
brain damage and memory loss. In posttreatment interviews, Malcolm also found 
that over 50% of the ECT patients reported side effects, with memory problems 
listed as their most common complaint.  
 A more recent investigation involving the review of 26 studies of patient 
perspectives on ECT found that over one third of patients reported significant 
memory loss after treatment, despite the lack of objective findings of memory 
impairment on standardized neuropsychological tests (Rose, Wykes, Leese, 
Bindman, & Fleischman, 2003). The authors of this study theorized that the 
contradiction between neuropsychological test findings and patient perspectives 
is a result of test choice. They point out that the neuropsychological measures 
commonly administered in ECT studies have typically examined anterograde 
amnesia or memory problems related to learning new material, while most 
patients complain of retrograde amnesia, or memory problems related to 
information they learned or knew prior to treatment. Rose et al. also suggest 
that this contradiction may be due to a lack of standardized neuropsychological 
measures designed to assess retrograde amnesia. 
 Recent advancements in the delivery of ECT treatment, including the 
introduction of brief and ultrabrief electrical pulse techniques, precise patient 
specific dosage titration, and variations in electrode placement all appear to help 
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diminish the negative cognitive effects of ECT without sacrificing treatment 
effectiveness (Sackeim et al., 2009). Yet fears of cognitive effects of ECT still 
exist. Therefore, to help clarify these issues for both patients and their 
physicians, it is necessary to continually assess approaches to ECT treatment and 
ascertain detailed information concerning cognitive side effects and treatment 
effectiveness. 
 
Focus on Electrode Placement 
 Since ECT was introduced in the 1930s, bitemporal (also referred to as 
bilateral) ECT, in which the electrodes are applied to both temples, has been the 
primary treatment modality. In response to widespread early findings that 
bitemporal ECT resulted in short-term memory loss and confusion, unilateral ECT 
was introduced in an effort to reduce these symptoms. In unilateral placement 
one electrode is placed on the temple above the cerebral hemisphere that is 
nondominant for language (usually the right), and a second electrode is placed 
near the vertex on the same side. Early findings suggested that unilateral 
placement spared memory functions, but was less effective in alleviating 
depression than bitemporal placement (UK ECT Review Group, 2003), although 
more current findings suggest right unilateral ECT can have nearly equivalent 
efficacy if delivered at much higher intensity (Sackeim et al., 1993). A third 
electrode placement was introduced by Inglis (1969). In light of his review of 
bitemporal and unilateral ECT, Inglis proposed that a more anterior, bifrontal 
placement of the electrodes might prove to be as effective as bitemporal and 
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unilateral placements while further sparing cognitive functions. This proposal was 
based on the premise that bifrontal ECT would avoid stimulation over the 
temporal lobes, which are known to be particularly important in the mediation of 
memory and learning. In bifrontal ECT electrodes are applied to the forehead 
above the eyes.  
 While bifrontal ECT has recently gained in popularity, research of it has 
remained limited, especially regarding its cognitive effects. This is in part due to 
the introduction of brief and ultrabrief pulse techniques; that is, procedures that 
are touted to reduce the cognitive effects of bitemporal ECT and therefore 
restore bitemporal placement to its original stature as the preeminent choice in 
clinical practice. Yet, the issue of effectiveness and severity of cognitive side 
effects of bifrontal ECT has not undergone the type of scrutiny to which other 
ECT methods have been subjected. As a result, the current study proposed to 
not only investigate the effectiveness of bifrontal ECT, but conduct a rigorous 
examination of the cognitive effects of this type of ECT treatment. To ensure as 
natural an approach as possible, bifrontal ECT was examined within the context 
of a typical treatment course for severe depression in a university-based 
psychiatric hospital. 
 Before reviewing the current study, a brief review of the research on the 
effectiveness of ECT in treating depression and the cognitive effects associated 




Overview of ECT Research 
Effectiveness of ECT in Treating Depression 
 The UK ECT Review Group recently conducted a meta-analysis of the 
published work on the efficacy and safety of ECT, comparing ECT to simulated 
ECT or pharmacotherapy, and comparing different electrode placements in ECT 
treatment. They concluded that treatment with ECT was significantly more 
effective than pharmacotherapy and that bitemporal ECT was moderately more 
effective than unilateral ECT (UK ECT Review Group, 2003). Furthermore, high 
dose ECT was described as more effective than low-dose procedures. Based on 
the findings of Sackeim et al. (2001), this review also reported that relapse rates 
were high following initial response to ECT. 
 Similarly, a meta-analysis conducted by Kho et al. (2003) also found 
superiority for ECT over medication treatment and some evidence that psychosis 
predicted better response to ECT. A study conducted by Prudic, Olfson, Marcus, 
Fuller, and Sackeim (2004) found comorbid personality disorders were associated 
with poorer ECT response. 
 The American Psychiatric Association’s (2010) Guidelines for the 
Treatment of Depression reported that the remission rates associated with ECT 
were between 70% and 90% in clinical trials. However, when investigated in 
community settings (general hospital ECT programs and outside of randomized 
controlled clinical trials), Prudic et al. (2004) found remission rates between 30% 
and 47% (with remission defined as a 60% or greater drop in HAM-D scores 
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from pre- to posttreatment and posttreatment scores less than 10). As stated 
above the two multisite studies reported remission rates ranging from 55 to 64% 
(Kellner et al., 2006; Sackeim et al., 2001). Prudic et al. also followed patients for 
24 weeks after ECT treatment and found that among initial remitters the relapse 
rate was 64.3% (with relapse defined as an increase of at least 10 points in 
HAM-D scores from posttreatment to follow-up and minimum HAM-D scores of 
16 for 2 consecutive weeks).  
Grunhaus, Hirschman, Dolberg, Schreiber, and Dannon (2001) also 
investigated relapse by tracking patients for 3 months who had successfully 
responded to a course of right unilateral or bitemporal ECT (response defined as 
HAM-D scores ≤ 10 and/or post-ECT Global Assessment Function Scale scores ≥ 
60 for 2 consecutive weeks). They found 10 of 35 patients relapsed within the 3-
month follow-up period (relapse defined as a return of at least 5 DSM-IV 
symptoms of Major Depressive Disorder and HAM-D scores ≥ 16), yielding a 
relapse rate of 28.5%. Previously, Sackeim et al. (1993) reported a 58% relapse 
rate among the 70 patients in their study who were initially classified as being 
responders to a course of bitemporal or right unilateral ECT. More than three-
quarters of these relapses occurred during the first 6 months following the 
completion of ECT. Sackeim et al. found no difference between electrode 
placements concerning relapse rates. 
 In summary, ECT is proven to be an effective treatment for severe 
depression, especially when individuals are at significant risk for suicide and 
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display psychotic symptoms (UK ECT review group, 2003). But relapse rates are 
high, with estimates ranging from nearly one-third to over two-thirds of those 
individuals who respond to the treatment. 
 
Cognitive Effects of ECT 
 Despite prevailing lay opinion that ECT causes many cognitive side effects, 
research has not been quite as definitive. An overarching theme found in the 
literature is that ECT induces varying levels of anterograde and retrograde 
amnesia (Lisanby, 2007) and subjective memory complaints (Squire & Slater, 
1983). Anterograde amnesia refers to difficulty remembering newly learned 
material, while retrograde amnesia refers to disturbances in memory for events 
or information learned prior to treatment.  
Concerning nonmemory cognitive side effects, empirical findings have 
been varied. Some studies reported differences between ECT and non-ECT 
treated patients on mental status and other cognitive measures (Calev, Gaudino, 
Squires, Zervas, & Fink, 1995) while others failed to demonstrate any negative 
nonmemory cognitive effects (Schulze-Rauschenbach et al., 2005). To further 
complicate issues, findings are often not comparable, due to significant 
differences in the number of ECT sessions administered, variations in electrode 
placement, and significant variability in the neuropsychological instruments 
utilized to assess cognition. These factors make general conclusions concerning 
the cognitive effects of ECT difficult. Despite these challenges, numerous studies 
have been conducted in an attempt to clarify these issues. Below, the major 
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findings from bitemporal and unilateral studies of ECT are presented, followed by 
a review of the literature specifically focusing on bifrontal ECT. 
 
Cognitive Effects of Bitemporal and Right Unilateral ECT 
 In a study comparing three groups of patients, those receiving bitemporal 
ECT, right unilateral ECT, or no ECT, Squire and Slater (1983) found patients’ 
subjective reports of memory problems were higher for the bitemporal ECT 
group than for the control group immediately posttreatment.  They found no 
differences between right unilateral placement and control groups. At 7 months 
follow-up, both ECT groups reported significantly higher subjective memory 
complaints than the control group. These findings suggested that patients 
treated with both bitemporal and right unilateral ECT perceive lasting problems 
with their memory. These findings are important, since ECT studies often fail to 
demonstrate impairments in memory on standardized cognitive measures, 
despite patients’ subjective complaints of memory impairment following a course 
of ECT treatment. 
 In a comparison of right unilateral ECT (n = 14), transcranial magnetic 
stimulation (rTMS, n = 16), and controls (n=15) in the treatment of major 
depression, Shulze-Rauschenbach et al. (2005) found that patients treated with 
right unilateral ECT showed greater anterograde memory problems at 
posttreatment testing than either the rTMS or healthy control groups. 
Specifically, following the presentation of an interference list, those treated with 
right unilateral ECT remembered fewer words from a target list on the Rey 
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Auditory Verbal Learning Test (AVLT) than did non-ECT treated patients. These 
findings indicated evidence of anterograde amnesia with right unilateral ECT.  
 Regarding retrograde amnesia, Schulze-Rauschenbach et al. (2005) found 
that right unilateral ECT patients were also disadvantaged compared to the rTMS 
and control groups. Specifically, they remembered fewer pictures and made more 
errors recalling words from visual and verbal stimuli presented prior to treatment. 
However, no differences were found concerning autobiographical memory when 
assessed with the Autobiographical Memory Interview (AMI). These findings are 
consistent with findings that retrograde memory, although generally impaired 
following bitemporal ECT (McElhiney et al., 1997, Sackeim et al., 2007), is less 
impaired following right unilateral ECT. Consistent with the findings from Squire 
and Slater (1983) concerning subjective complaints, patients who received right 
unilateral ECT also subjectively reported more memory problems than the rTMS 
patients and controls (Schulze-Rauschenbach et al., 2005).   
 Shulze-Rauschenbach et al. found no differences between groups on any 
of the nonmemory cognitive measures administered in the study. Those 
measures included mental status, executive functions, auditory working memory, 
verbal fluency and processing speed as measured by the Mini-Mental State Exam 
(MMSE), Trail Making Test conditions A and B, Wechsler Digit Span subtest, Word 
Fluency test, and Letter-Number span tests, respectively. Their findings 
suggested that memory, but not other cognitive functions, appears susceptible to 
adverse treatment effects from right unilateral ECT procedures. 
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 Furthermore, the rTMS group in the Shulze-Rauschenbach et al. study 
(2005) showed improvement for several memory measures from pre- to 
posttreatment. This suggests that when the rTMS patients' depression was 
alleviated, their memory may actually have improved, while the opposite effect 
was observed for the right unilateral ECT group, that is, their memory worsened 
below the initial levels associated with their depression. 
 These findings, that right unilateral ECT patients demonstrated no 
significant nonmemory effects, were inconsistent with previous conclusions 
drawn by Calev et al. (1995). These authors conducted a review of studies 
published since 1975 of only nonmemory cognitive effects of ECT and concluded 
that ECT did, in fact, cause nonmemory cognitive deficits for many patients. 
Despite recovery from depression, in which cognitive performance is expected to 
improve, Calev et al. found no improvement for ECT patients on several 
measures of cognition taken immediately posttreatment (48-72 hours). This was 
suggestive of nonmemory cognitive deficits resulting from ECT. Specifically, their 
review revealed that during the time immediately posttreatment, ECT patients 
deteriorated from baseline on measures of verbal fluency. Furthermore, they 
found a lack of evidence of improvement on measures of motor functions, 
perceptual and visuospatial functions, executive functions, and general 
intelligence testing from pre- to posttreatment for the ECT group. These findings 
suggested that many nonmemory functions may be impacted by ECT treatment 
in addition to the negative effects resulting from depression itself.  
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 By the follow-up phases of these studies, which ranged from 1 week to 7 
months posttreatment, Calev et al. (1995) found that nearly all measures 
improved over baseline or returned to baseline functioning. This suggested that 
the preponderance of negative effects of ECT on nonmemory cognitive processes 
found immediately posttreatment were alleviated within a brief period of time. 
The authors asserted that results concerning frontal lobe functioning (executive 
processes) were inconclusive and required further exploration. Further, the 
studies reviewed by Calev et al. employed either bilateral or right unilateral ECT 
electrode placement, but the authors made no distinctions between the two 
placements in terms of their differing cognitive effects. Therefore, from their 
review, it is not possible to make conclusions concerning nonmemory cognitive 
impairments due to different electrode placements. Nevertheless, the conclusion 
that any nonmemory cognitive impairments observed immediately posttreatment 
appear short in duration, regardless of electrode placement, is an important 
contribution of their review. 
 Sackeim et al. (2007) recently conducted a large-scale, prospective study 
of memory and other cognitive effects of ECT. In the study, 347 patients received 
either bitemporal or right unilateral ECT. The patients were evaluated 
pretreatment, immediately posttreatment, and approximately 6 months following 
treatment cessation. An extensive neuropsychological test battery was 
administered each time. The battery included measures of mental status 
(MMSE), psychomotor functioning (simple, choice, and Stroop reaction time 
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tasks), anterograde learning and memory (Complex Figure Test and the Buschke 
Selective Reminding Test), and retrograde amnesia (Autobiographical Memory 
Interview - Short Form).  
A prominent finding of Sackeim et al. (2007) was that there were 
differences on measures of mental status, psychomotor speed, and retrograde 
amnesia between people receiving ECT at each treatment facility largely due to 
variations in ECT electrode placement and stimulation techniques. Specifically, 
the use of sine wave stimulation and bitemporal electrode placement were 
associated with greater short-term and long-term cognitive deficits. In particular, 
compared to brief pulse stimulation, sine wave stimulation had a greater 
negative effect on psychomotor response speed for two of the three reaction 
time tasks immediately posttreatment and at 6 months follow-up. In terms of 
memory effects, patients treated with bitemporal ECT had significantly greater 
amnesia for autobiographical information at both immediate and follow-up 
testing points compared to right unilateral ECT patients. This was consistent with 
previous findings that right unilateral ECT results in fewer cognitive side effects 
than bitemporal ECT (Sackeim et al. 1993). Compared to the right unilateral 
group, the bitemporal ECT group showed an average of 3.4 times more 
forgetting from pre- to posttreatment, and 2.8 times more amnesia at 6 months 
follow-up when assessed with the Autobiographical Memory Interview - Short 
Form (AMI). These findings suggest substantial deficits in retrograde memory for 
patients treated with bitemporal ECT. 
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In summary, the research suggests that memory dysfunction is the main 
cognitive impairment that may result from ECT treatment. Retrograde amnesia is 
the most common persistent adverse effect. Any nonmemory cognitive effects 
observed appear to be transient in nature. Furthermore, these studies show 
evidence that bitemporal ECT results in greater memory impairment than right 
unilateral ECT, which itself results in greater memory impairment than non-ECT 
treatments. Subjectively, patients often seem to report significant levels of 
memory impairment and confusion that research has failed to quantify. 
 
Effectiveness and Cognitive Effects of Bifrontal ECT 
Bifrontal electrode placement was initially adopted to avoid direct 
stimulation of the temporal and hippocampal areas, which are known to mediate 
human learning and memory. Unfortunately, research is not comprehensive 
concerning the effectiveness and cognitive effects of ECT conducted in this 
fashion. Some have suggested that the frontal lobe activation resulting from 
bifrontal electrode placement may have equally adverse consequences for 
executive functions as bitemporal placement has for memory functions (Crowley, 
Pickle, Dale, & Fattal, 2008). There is limited research into the effects of bifrontal 
ECT, specifically its effects on frontal lobe or executive functions. In fact, two 
recent meta-analytic reviews of the efficacy and safety of ECT failed to address 
bifrontal placement at all, reviewing only those studies employing bitemporal or 
right unilateral electrode placement (Kho et al., 2003; UK ECT Review Group, 
2003). The limited number of studies investigating bifrontal electrode placement 
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in ECT are reviewed below. 
In the Crowley et al. (2008) review of the research investigating the 
efficacy and cognitive side effects of bifrontal ECT the authors concluded that 
this electrode placement has clinical efficacy at least comparable to the 
traditional placements of right unilateral and bitemporal in treating severe 
depression. A recent study by Kellner et al. (2010) corroborated these findings 
by demonstrating that all three electrode placements are effective antidepressant 
treatments when administered at appropriate electrical dosing, although 
bitemporal placement resulted in more rapid symptom reduction. Similarly, 
Bailine et al. (2000) and Letemendia et al. (1993) concluded that bifrontal 
electrode placement was as efficacious in relieving depression as bitemporal and 
right unilateral placement, while resulting in less cognitive impairment. Based on 
studies conducted by Bailine et al. (2000) and Ranjkesh, Barekatain, and 
Akuchakian (2005) that found higher Mini-Mental State Exam (MMSE) scores for 
bifrontal versus other electrode placements, Crowley et al. concluded that 
bifrontal ECT produced fewer cognitive side effects than other electrode 
placements.  
 In an attempt to assess the clinical efficacy of bitemporal and bifrontal 
placements, Bakewell, Russo, Tanner, Avery, and Neumaier (2004) conducted an 
analysis of 76 patients’ charts. The researchers concluded that, compared to 
bitemporal ECT, bifrontal ECT resulted in less impairment in cognitive variables 
such as confusion, disorientation, memory loss, and the need for assistance in 
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daily routines. An obvious limitation of the Bakewell et al. (2004) study, however, 
is its lack of standardized measures assessing cognitive impairment, despite the 
fact some might consider this method a strength, given the limitation of 
standardized measures in capturing the subjective experiences and adaptive 
behaviors of patients (behaviors that were investigated by Bakewell et al.). 
To date, Lawson et al. (1990) and Kellner et al. (2010) have conducted 
the most in-depth studies designed to assess the cognitive effects of bifrontal 
ECT.  Both studies investigated the differential effects on cognition of all three 
electrode placements in ECT.  
Lawson et al. (1990) administered measures of verbal intelligence, verbal 
memory, nonverbal intelligence, and planning and sequencing to individuals in all 
three electrode placements groups. Verbal intelligence was evaluated by 
combining the Wechsler Adult Intelligence Scales - Revised (WAIS-R) subtests of 
Information and Vocabulary to create a composite score yielding a Verbal IQ. The 
researchers found that immediately following six treatments, the right unilateral 
and bifrontal groups performed superior to the bitemporal group on this measure 
of Verbal IQ, but by 7 days and 3 months posttreatment all differences between 
verbal functions for the three electrode placements had diminished. They also 
created a composite score for verbal anterograde memory by combining the 
Wechsler Memory Scale logical memory immediate and delayed recall conditions. 
Those results found that both the right unilateral and bifrontal groups performed 
superior to the bitemporal group on measures of anterograde verbal memory 
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immediately posttreatment, but not at 7 days or 3 months follow-up. The authors 
therefore concluded, despite observations of immediate differences in verbal 
functioning and anterograde memory, that no lasting cognitive differences were 
found between the three variations in electrode placements.  
To the contrary, the more recent study conducted by Kellner et al. (2010) 
found that the bifrontal group scored inferior to the other two electrode 
placements in verbal anterograde memory (AVLT immediate and delayed tests), 
but that there were no differences between electrode placements in nonverbal 
anterograde memory.  (The latter study used the Rey Auditory Verbal Learning 
Test (AVLT) to assess verbal anterograde memory and the Rey-Osterrieth and 
Taylor Complex Figure Tests to assess nonverbal anterograde memory.) Also 
contrary to earlier findings, Kellner et al. identified no advantages to right 
unilateral ECT in memory functions when compared to bitemporal placement. 
Regarding retrograde memory, Kellner et al. reported a trend toward inferiority of 
scores in the bifrontal group compared to right unilateral and bitemporal ECT 
groups on the Autbiographical Memory Interview.  However, these results were 
not statistically significant. 
 Lawson et al. (1990) also examined nonverbal reasoning after ECT. The 
researchers found no differences between the three electrode placements in 
nonverbal intelligence as assessed by combining the WAIS-R Block Design and 
Object Assembly subtests into a composite score. 
 The Trail Making Test was used to evaluate the executive functions of 
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planning and sequencing after ECT in the studies of both Lawson et al. (1990) 
and Kellner et al. (2010). As with nonverbal functions, there were no reliable 
group differences found at any point between the three electrode placements. 
Kellner et al. also administered the Category Fluency test, Stroop Color Word 
Test, the Controlled Word Association Test, and the D-KEFS Sorting Test to 
assess executive functions. They found no evidence of differential effects for any 
of the three electrode placements. 
 Eschweiler et al. (2007) and Heikman et al. (2002), much like Kellner et 
al. (2010), found no results supporting the conclusion that bifrontal ECT results 
in less memory impairment compared to other electrode placements. In the 
study conducted by Eschweiler et al., 92 patients received six right unilateral ECT 
treatments or six bifrontal ECT treatments over a 3-week period. The findings 
suggested equal clinical efficacy in reducing depression for the two treatments, 
and no differences in mental status between them as measured with the MMSE. 
However, a shortcoming of their study relates to the relatively small number of 
treatments provided (6), as a typical ECT series ranges from 6 to 12 ECT 
treatments. Similar to Eschweiler et al., Heikman et al. found no differences in 
MMSE scores between three randomized groups who received high-dose right 
unilateral ECT, moderate-dose right unilateral, or low-dose bifrontal ECT.  
In terms of clinical efficacy, Heikman et al. found more clinical 
improvement in depression symptoms, as rated by the HAM-D, for the high-dose 
right unilateral group compared to the moderate-dose right unilateral or low-dose 
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bifrontal groups. Results of these studies challenge findings that bifrontal ECT is 
associated with fewer cognitive side effects and comparable efficacy when 
compared to the other two groups. Yet these conclusions are limited by the 
assessment of cognitive functions only with the MMSE. 
 In summary, few studies have done a thorough job of investigating the 
cognitive effects of bifrontal ECT. What is clear is that bifrontal ECT is at least as 
efficacious as bitemporal and right unilateral ECT when administered at the 
proper dosing. The most recent investigation by Kellner et al. (2010), which 
compared the cognitive effects of all three placements, suggests that bifrontal 
ECT may actually result in greater anterograde amnesia for verbal information, 
but found no other statistically significant differences between electrode 
placements in other areas of cognition. 
 
Purpose of Research 
This study was designed to contribute to the limited scientific literature 
regarding the effectiveness and cognitive side effects of bifrontal ECT.  Although 
bifrontal electrode placement has been gaining in popularity, there have been 
few investigations of the cognitive side effects of ECT conducted in a thorough 
fashion. Given concerns about side effects of ECT, in particular, potential 
persistent problems with memory, the following research questions were 




1. How effective is bifrontal ECT in alleviating symptoms of depression 
immediately posttreatment and at 1-month follow-up? 
2. Do participants treated with bifrontal ECT display difficulties with 
retrograde and anterograde amnesia immediately posttreatment and at 1-
month follow-up? 
3. What are the effects of bifrontal ECT on participants’ performance on 
measures of executive functioning immediately posttreatment and at 1-
month follow-up? 
4. What are the effects of bifrontal ECT on participants’ performance on 






 The present study was initially approved as part of a larger pilot study led 
by Howard Weeks, MD, a faculty member in the Department of Psychiatry at the 
University of Utah and psychiatrist at the University Neuropsychiatric Institute. 
Weeks’ study set out to investigate the effectiveness and cognitive side effects of 
both bifrontal ECT and an experimental treatment for depression involving 
repeated Isoflurane anesthesias. The Institutional Review Board at the University 
of Utah was confirmed on 1/23/2008, (IRB #00025750). A substudy of the larger 
study aiming to investigate only the effectiveness and cognitive side effects of 
bifrontal ECT received Institutional Review Board approval on 4/21/2010 (IRB 
#00025750). The data used for the present study were drawn from both the 
larger study and substudy. Sources and selection criteria for participants of the 
present study are discussed below. 
 
Recruitment and Selection 
Participants were recruited from among patients referred for ECT through 
a university-based psychiatric hospital ECT program, where approximately 2,000 
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treatment sessions are administered each year. Individuals from 18 to 65 years 
of age who displayed significant unipolar or bipolar depression and had been 
recommended by a psychiatrist for ECT treatment were invited to participate. 
Nineteen participants who had agreed to receive ECT treatment consented to 
participate in the current study. After consent was provided, 1 participant 
withdrew from the study while attempting to complete baseline 
neuropsychological testing due to extreme emotional distress, and a 2nd 
participant withdrew just prior to follow-up testing, reporting disappointment 
with the effects of the ECT treatment. This individual indicated he did not wish to 
have his baseline or posttreatment data included for analysis.  Of the 17 
remaining participants, 11 were male and 8 female. The study participants 
ranged in age from 23 to 62. Nine were involved in inpatient treatment, and 10 
received treatment in an outpatient setting. All participants, however, had a 
documented history of severe depression unsuccessfully treated by at least two 
different medications during a 2-year period or more and had severe enough 
depression at the time of this study to warrant psychiatrist referral for ECT. 
Further, patients being treated in outpatient care were offered the choice to 
enroll in a series of Isoflurane anesthesia or bifrontal ECT treatments, while 
patients receiving inpatient care were offered participation in the bifrontal ECT 
condition only. It should be noted that all participants in the current study were 
maintained on usual medical treatment, including psychopharmacotherapy and 
psychoptherapy, while undergoing ECT.  
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 Exclusionary criteria used in the study included 1) a diagnosis of primary 
psychotic disorder, dysthymia, or personality disorder; 2) significant premorbid 
cognitive impairment; 3) unstable symptomatic coronary artery disease, poorly 
compensated congestive heart failure, history of transient ischemic or neurologic 
signs during the past year, or history of susceptibility to malignant hyperthermia; 
4) any other contraindication to Isoflurane anesthesia; or 5) deemed 
incompetent to provide consent.   
 
Setting and Procedures 
 Assessment of study participants took place in the ECT wing or on the 
inpatient ward of a university-based psychiatric hospital. Testing was conducted 
in a one-to-one format. Data were collected over a period of 15 months from 
2009-2010. 
 Each potential participant was given a full verbal explanation of the study 
procedures including risks, benefits, and alternatives, and offered a copy of their 
signed written consent form (Appendix A). Potential participants were given the 
opportunity to review the consent form and discuss any questions or concerns 
with their own psychiatrist, study investigators, or others if necessary, a 
minimum of 1 day prior to beginning the study treatment procedures. Anyone 
judged by the referring psychiatrist or study psychiatrist as incompetent to give 
informed consent for the study was considered ineligible for participation 
(incompetence as defined by the inability to understand the risks associated with 
the procedures or alternative treatments, such as impaired cognitive functioning 
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or severe psychosis).  
 Participants received a series of ECT treatments, ranging from 7 to 12 per 
participant, over a 2 1/2- to 3 1/2-week period. All treatments were administered 
at a university-based psychiatric hospital. Participants received standard 
recommended monitoring and follow-up health care from hospital physicians and 
medical staff. 
 Participants completed a battery of psychiatric and neuropsychological 
measures (described below) within the week prior to beginning treatment and 
within 24 to 48 hours after treatment concluded. Follow-up testing was also 
conducted approximately 1 month (4 to 5 weeks) after the end of the treatment. 
Of the 17 participants, 13 completed all test measures. One participant could not 
complete one computerized test that relied on speeded verbal fluency of the 
English alphabet because English was not his first language and he 
demonstrated poor alphabetic fluency. Two participants’ computerized data could 
not be used due to technical failure of the computerized testing equipment. One 
participant who resided over 5 hours away could not return to the university-
based hospital for follow-up testing. Therefore computerized data and pencil 
paper tests (Coding and Symbol Search from the Wechsler Adult Intelligence 
Scale – III) could not be administered. Examiner error resulted in invalid test 
administration of the Logical Memory I and II subtests from the Wechsler 
Memory Scale – Third Edition at posttreatment for the 4th participant. Therefore, 




 Participants were assigned an identification number to which all data were 
linked. Except for birth date, which was required for scoring many of the 
measures, all personal identifiers were removed from the data used in the 
analyses. The data were kept in a secure location in the office of the principal 
investigator of the larger study, a psychiatrist at the hospital where the study 
took place. 
 The primary investigator and two research assistants trained in 
neuropsychological assessment administered all measures according to 
standardized procedures. Participants were observed for signs of fatigue or 
distress during the assessments and offered opportunities for breaks. All 
protocols were scored by the individual administering the testing and the primary 




 Participants in the study underwent psychiatric and neuropsychological 
assessments, listed in Table 1. Specifically, participants completed a series of 
standardized cognitive tests designed to assess memory, mental processing 
speed, executive functioning and motor control, lasting approximately 50 to 60 
minutes.  At pretreatment only, participants also completed the Wechsler Test of 
Adult Reading (WTAR), a 3-minute, 50-item oral reading task that provides an 








Depression Hamilton Depression Inventory – 24 Item (HAM-D) 
  








Hopkins Verbal Learning Test – Revised (HVLT-R, 
Immediate Recall and Delayed Recall) 
 
Wechsler Memory Scale – III, Logical Memory I & II 
(WMS-III, LMI & LMII) 
  
Processing Speed Wechsler Adult Intelligence Scale – III (WAIS-III) Digit-





Delis-Kaplan Executive Functioning Scales (D-KEFS), 
Verbal Fluency Test (FAS) 
 
Behavioral Dyscontrol Scale - Electronic Version (BDS-
EV), Alphanumeric Sequencing Test, Simple Choice 









follow-up, participants completed 12 tests that comprised the study’s testing 
battery, including the Hamilton Depression Inventory, Mini-Mental State Exam, 
Autobiographical Memory Interview, Hopkins Verbal Learning Test - Revised, 
Wechsler Memory Scale - Third Edition Logical Memory subtests, Wechsler Adult 
Intelligence Scale - Third Edition Processing Speed subtests (Symbol Search and 
Digit Symbol Coding), four subtests from the Behavioral Dyscontrol Scale - 
Electronic Version, and the FAS test of verbal fluency. Participants also responded 
to two questions designed for the study assessing subjective memory impairment 
and perceived treatment effectiveness (Appendix B). The subjective memory 
impairment question was administered at all three testing sessions, while the 
treatment effectiveness question was only administered at follow-up testing. 
 
Depression 
 The Hamilton Depression Inventory (HAM-D; Hamilton, 1967) was used to 
assess depressive symptomatology in all participants at pretreatment, 
posttreatment, and follow-up testing sessions. This study utilized the 24-item 
interview which rates the severity of symptoms observed in depression such as 
low mood, insomnia, agitation, anxiety and weight loss. The questionnaire is one 
of the most commonly used scales for rating depression in medical research. The 
investigator rates the patient by interviewing them and observing the patient's 
symptoms. Each question has from three to five possible responses that increase 
in severity. The total score represents a sum of the values for the questions. 
Scores under nine indicate the absence of diagnostically significant depression. 
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Scores ranging from 10 to 19 indicate mild depression symptomatology, 20 to 29 
indicate moderate depression, and scores above 30 are interpreted as indicating 
severe depression. The maximum score one can receive on this measure is 66. 
 
Mental Status 
 The Mini-Mental State Exam (MMSE; Folstein, Folstein, & McHugh, 1975) 
was given to assess mental status. This is a brief 30-point questionnaire that is 
used to screen for cognitive impairment in many clinical settings. The MMSE 
includes simple questions and items assessing several areas, including time and 
place orientation, immediate auditory memory, motor functioning, and visual 
perception. Any score greater than or equal to 25 points (out of 30) is considered 
normal (intact), and scores below 25 points may indicate severe (≤16), moderate 
(17-21), or mild (21-24) cognitive impairment. 
 
Retrograde Memory 
 Retrograde amnesia was assessed with the Autobiographical Memory 
Interview - Short Form (AMI, McElhiney, Moody, & Sackeim, 1997). This 
instrument was developed specifically for the purpose of examining the nature of 
amnesia following ECT, and allows the quantification of retrograde amnesia 
following ECT treatment. To accomplish this, the participant was asked a series 
of detailed autobiographical questions prior to ECT. The questions probed for 
specific details for six sets of events or experiences, most of which occurred 
during the previous year. The six domains inquired in detail about the 
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participant's most recent employment, birthday celebration, New Year's Eve 
activities, information about a close relative, recent travel, and most recent 
physical complaint for which they sought medical care. Each of these six domains 
contained six specific questions (i.e., Where did you celebrate your last 
birthday?) These same questions were asked again at posttreatment and follow-
up. Thus, the participant’s answers prior to treatment were used as a template 
against which subsequent answers were compared. The comparison of the 
posttreatment answers with the answers given prior to treatment yielded 
“amnesia scores” in the form of percentiles. Individual norms have not been 
developed for this instrument, yet it remains the primary outcome measure for 
personally relevant autobiographical memory currently utilized in ECT research. 
 
Anterograde Memory 
 Two separate tests were administered to measure verbal learning and 
memory. These include the Hopkins Verbal Learning Test – Revised Immediate 
Recall and Delayed Recall conditions (HVLT-R; Brandt & Benedict, 2001) and the 
Wechsler Memory Scale - Third Edition Logical Memory subtests, Immediate and 
Delayed (WMS-III LM I & II; Wechsler, 1997). The HVLT-R is a word list-learning 
task where 12 words are presented over three learning trials. At the end of each 
trial the participant provided as many of the words from the list as he/she could 
recall. After a 20- to 25-minute time delay, the participant was asked to recall as 
many words as they were able from memory. The final task required participants 
to discriminate which words were on the original list from a longer list in a forced 
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choice (yes versus no) paradigm. Raw scores were converted to T-scores (M=50, 
SD=10) to yield scores for total recall (a composite score from the first three 
trials), delayed recall, % retention, and recognition discrimination. Benedict, 
Schretlen, Groniger, and Brandt (1998) conducted test-retest reliability analyses 
in older adults, with a mean test-retest interval of 6 weeks. Reliability for the four 
primary HVLT-R variables were .74 for total recall, .66 for delayed recall, .39 for 
% retention, and .40 for recognition discrimination. 
 The WMS-III Logical Memory subtests were used to assess auditory recall 
under immediate and delayed conditions. In the immediate condition (Logical 
Memory I) the participant listened to two stories and retold the details of the 
stories over three trials, one trial for story 1 and two trials for story 2. The 
participants’ raw score for all three trials was summed and converted to a subtest 
scaled score (M = 10, SD = 3). After a 25- to 35-minute delay (Logical Memory 
II), the participant was asked to retell the details of the two stories. In this case, 
the raw scores from the two trials were summed and converted to scaled scores. 
The split-half reliability coefficients, providing measures of internal consistency, 
were reported in the manual for both subtests (Wechsler, 1997b). Averaged 
across all age groups, the reliability coefficient for Logical Memory I was .88 and 
for Logical Memory II was .79, indicating high internal consistency. Test-retest 
reliability coefficients, providing estimates of the subtest stability over time, were 
also reported. Averaged across all age groups, the test-retest reliabilities for 
Logical Memory I and Logical Memory II were .77 and .76, indicating moderately 
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high stability over time. 
 Shapiro, Benedict, Schretlen, and Brandt (1999) examined the correlations 
between HVLT-R total recall, delayed recall, and percent retention, and 
comparable measures from the Logical Memory subtests of the Wechsler Memory 
Scale - Revised (WMS-R). They found the highest correlation with HVLT-R total 
recall with Logical Memory I (r=.75) and the highest correlation with HVLT-R 
delayed recall with Logical Memory II (r=.77). This suggests that the HVLT-R 
total recall and WMS-R Logical Memory I subtest may be capturing similar facets 
of immediate anterograde memory, while the HVLT-R delayed recall and WMS-R 




 Processing speed was assessed using the Digit Symbol-Coding (Coding) 
and Symbol Search subtests from the Wechsler Adult Intelligence Scale – 3rd 
Edition (WAIS-III; Wechsler, 1997a). Raw scores were converted to scaled scores 
(M=10, SD=3), and the two subtest scaled scores were combined to form a 
composite reflecting processing speed. This composite (Processing Speed Index) 
results in a standard score (M=100, SD=15) describing a person's speed of visual 
scanning, visual discrimination, and graphomotor speed. Both subtests are 
administered under a 2-minute time limit. 
 Reliability coefficients reported in the manual, in the form of test-retest 
reliabilities averaged across all age groups, were .86 and .79 for Digit Symbol-
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Coding and Symbol Search, respectively. The Processing Speed Index 
demonstrated high test-retest reliability across all age groups with a coefficient 
equal to .89. 
 
Executive Functioning and Motor Control 
 Four subtests from the Behavioral Dyscontrol Scale - Electronic Version 
(BDS-EV; Suchy, Derbidge, & Cope, 2005) were administered to assess various 
aspects of executive functioning and motor control. The BDS-EV comprises a 
series of subtests administered via computer. Participants responded to the tasks 
on a response box designed for use with this test battery. The subtests 
administered included Branching Go-No-Go, Push-turn-taptap, Alphanumeric 
sequencing, and Simple choice reaction time. Branching Go-No-Go, a test 
requiring subjects to respond differentially to shapes and squares, measured 
both reaction time and decision speed. Push-turn-taptap, a test requiring 
participants to rapidly perform a series of one or more hand movements from 
memory, provided a measure of motor programming, inhibition, and working 
memory. The Alphanumeric sequencing subtest, designed to measure aspects of 
working memory and visual scanning, required participants to complete a 
letter/number sequence by pushing buttons on both the left and right hand sides 
of the response box. The last test from the BDS-EV battery is the Simple choice 
reaction time task, measuring reaction time. In this task participants pushed a 
button as quickly as possible to match the color of a circle shown on the screen.  
 The tests of the BDS-EV have demonstrated adequate reliability on 
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measures of internal consistency, with Cronbach’s alpha values ranging 
approximately from .70 to 87. Furthermore, Suchy, Derbidge, and Cope (2005) 
found moderate to strong convergent evidence with the Behavioral Dyscontrol 
Scale, a paper-pencil format from which the electronic battery was derived. 
 
Verbal Fluency 
 The FAS verbal fluency test was administered and scored according to 
standard procedures set forth in the Delis-Kaplan Executive Functioning Scales 
(D-KEFS; Delis, Kaplan, & Kramer, 2001a). This test required participants to 
name as many words as they could beginning with the letters "F", "A", and "S" 
under 1-minute time constraints. The raw scores for each letter condition were 
summed and converted to standard scores using the D-KEFS norms (M = 10, SD 
= 3). According to the D-KEFS technical manual (Delis, Kaplan, & Kramer, 
2001b), the letter fluency condition (FAS) has demonstrated strong split-half 
internal consistency measures with an average correlation of .85 for all the adult 
age groups. Similarly, the test has been shown to have adequate test-retest 
reliability for all ages (r=.80). 
 
Premorbid Cognitive Level 
 Pretreatment cognitive functioning was estimated using the Wechsler Test 
of Adult Reading (WTAR; Wechsler, 2001). This instrument, which was co-
normed with the WAIS-III (and WMS-III), was designed to provide a measure of 
premorbid cognitive functioning prior to the onset of an injury or illness. Word 
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reading has been found to be relatively resistant to the negative impact of 
neurologic insult, including traumatic brain injury, and other illnesses or 
conditions that have been shown to affect cognitive ability, including depression.  
The WTAR requires that a person read 50 words aloud. Raw scores are 
then converted to standard scores (M=100, SD=15) to estimate intellectual 
functioning. According to the WTAR manual, internal consistency measures using 
alpha coefficients range from .90-.97 for the different age groups in the U.S. 
standardization sample. Test-retest reliability coefficients have been shown to be 
similarly high, that is, .90 to .94. The reported correlation of the WTAR score 
with the WAIS-III Full Scale IQ score is .73 for the total standardization sample.  
 
Subjective Questions 
 Two subjective questions were created for use in this study. The first 
asked participants to rate their memory over the past 24 hours on a scale of one 
to seven, with a one rating reflecting no observed memory difficulties and a 
seven rating reflecting severe observed memory difficulties. This question was 
administered at pretreatment, posttreatment, and follow-up testing sessions. The 
second question, administered only at follow-up, asked participants to rate the 
effectiveness of their treatment on a scale of one to seven, with one reflecting an 





 The larger ECT and Isoflurane study and neurocognitive effects substudy 
from which the data for this study were drawn represents a repeated measures 
design. The repeated measures factor involves the analysis of depression and 
cognitive effects of participants who received ECT over three points in the course 
of treatment: pretreatment, posttreatment, and follow-up. 
 
Data Analyses 
 The performance of participants on individual measures was described 
using measures of central tendency and variability. Means and standard 
deviations of the continuous variables were calculated for the sample. Frequency 
of categorical variables (e.g., gender) was determined and tabulated for the 
sample. Range of scores was calculated for each measure. Research questions 
were addressed through repeated measures analysis of variance comparing 
mean differences across the three points in treatment with a statistical 





 As seen in Table 2, the 17 participants who completed all phases of the 
study ranged in age from 23 to 62. Mean age of the 17 participants in the total 
sample was 41.71 with a standard deviation of 11.66. Data from 10 males (59% 
of the sample) and 7 females (41% of the sample) were included. Seven of 
these participants received treatments as part of their inpatient hospital care 
(41% of the sample) and 10 received outpatient treatment (59% of the sample). 
Premorbid cognitive level was assessed with the Wechsler Test of Adult Reading 
(WTAR). The mean WTAR score was 107.71, with a standard deviation of 8.99 
and range from 87 to 125. WTAR scores falling between 85 and 115 are 
classified as average. Participants received between 7 and 12 treatments in their 
series, with an average of 9.06 treatments (SD=1.35). The majority of the 
participants in this study met the DSM-IV criteria for Major Depressive Disorder, 
severe and recurrent, without psychotic features, as their primary diagnosis. One 
individual received a primary diagnosis of Major Depressive Disorder, severe and 
recurrent, with psychotic features, and 1 received a primary diagnosis of Bipolar 







Participant Demographics for Gender, Age, Premorbid Cognitive Level, 
Inpatient/Outpatient Status, and Number of Treatments Received 
Demographic Total Sample 
  
Males (% of sample) 10 (59%) 
  
Females (% of sample) 7 (41%) 
  
Age – M(SD) 41.71 (11.66) 
  
Premorbid Cognitive Level on WTAR– M(SD) 107.71 (8.99) 
  
Inpatient Status (% of sample) 7 (41%) 
  
Outpatient Status (% of sample) 10 (59%) 
  




(4 individuals), Alcohol Abuse or Dependence (3), Cannabis Abuse or 
Dependence (3), Opoid Dependence (1), Obsessive Compulsive Disorder (1), 
Dysthymic Disorder (1), Anxiety Disorder NOS (3), Post-Traumatic Stress Disorder 
(2), and Panic Disorder without Agorophobia (1). Individual participant 
demographic data are displayed in Table 3. 
 
Research Question 1 
How effective is bifrontal ECT in alleviating symptoms of depression 
immediately posttreatment and at 1-month follow-up?  Data from the HAM-D 
interview, displayed in Table 4, show that 15 of the 17 participants who 
completed the HAM-D prior to treatment had scores falling in the severely 
depressed range. According to Hamilton (1967), scores > 30 constitute severe 
depression, whereas scores of 20-29 indicate moderate depression, scores of 10-
19 indicate mild symptoms, and scores ≤9 indicate no depression. Immediately 
posttreatment 8 participants had HAM-D scores in the range indicating no 
depression (score < 9), 7 had scores in the mildly depressed range (scores 10-
19), 1 demonstrated moderate depression (20-29), and 1 had severe depression 
> 30. These data indicate that the majority of the participants responded to 
bifrontal ECT treatment. At 1-month follow-up, three HAM-D scores fell in the 
range indicating no depressive symptoms, seven in the mild range, six in the 




















1 60/Female 8 Inpatient 296.33: Major Depressive Disorder, Recurrent, 
Severe Without Psychotic Features  
None 107 
2 47/Female 8 Inpatient 296.33 Anxiety Disorder NOS, Panic Disorder 
Without Agorophobia 
117 
3 28/Male 10 Outpatient 296.33 Generalized Anxiety Disorder 105 
4 32/Male 8 Outpatient 296.33 Generalized Anxiety Disorder, Alcohol Abuse 98 
5 40/Male 8 Inpatient 296.33 Anxiety Disorder NOS 108 
6 23/Male 10 Outpatient 296.33 Generalized Anxiety Disorder 87 
7 62/Male 8 Inpatient 296.33 Alcohol Dependence, Cannabis Dependence 107 
8 31/Female 9 Outpatient 296.53: Bipolar I Disorder, Most Recent Episode 
Depressed, Severe Without Psychotic Features 
Opiod Dependence 106 
9 31/Male 8 Inpatient 296.34: Major Depressive Disorder, Recurrent, 
Severe With Psychotic Features 
Obsessive-Compulsive Disorder 109 
10 43/Male 8 Outpatient 296.33 None 113 
11 48/Male 9 Outpatient 296.33 None 119 
12 47/Female 11 Outpatient 296.33 Dysthymic Disorder, Anxiety Disorder NOS 125 
13 52/Male 12 Inpatient 296.33 Cannabis Dependence, Post Traumatic 
Stress Disorder 
102 
14 31/Female 10 Outpatient 296.33 Generalized Anxiety Disorder, Panic Disorder 
Without Agorophobia, Alcohol Abuse, 
Cannabis Abuse 
117 
15 45/Female 10 Outpatient 296.33 None 98 
16 55/Female 7 Inpatient 296.33 Anxiety Disorder NOS, Post Traumatic 
Stress Disorder 
107 







Classifications, Means, and Standard Deviations at Pretreatment, Posttreatment, 
and Follow-up for Hamilton Depression Inventory (HAM-D) 
Classification Pretreatment Posttreatment Follow-up 
    
Number of HAM-D scores in 
“No Depression” Range 0 8 3 
    
Number of HAM-D scores in 
“Mild Depression” Range 1 7 7 
    
Number of HAM-D scores in 
“Moderate Depression” Range 1 1 6 
    
    
Number of HAM-D scores in 
“Severe Depression” Range 15 1 1 
    








    
Average % Reduction in 
Mean HAM-D Symptoms from 
Pretreatment 
 72.78% 59.33% 
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These data show that 10 participants, over half, demonstrated negligible or low 
levels of depressive symptomatology at the time of follow-up, whereas 7 
participants demonstrated moderate to severe levels of depressive symptoms at 
follow-up, or one month following the cessation of ECT treatment.  
According to some ECT researchers, response to treatment is defined as a 
50% reduction in depressive symptoms on the HAM-D (Eschweiler et al., 2007; 
Kellner et al., 2010; Sackeim et al., 2007; Schulze-Rauschenbach et al., 2005). 
Results of the current study showed that 15 of the 17 participants (88.24% of 
the sample) who completed HAM-D interviews at all three assessment points had 
at least a 50% reduction in depressive symptoms as measured by the HAM-D 
interview posttreatment. At 1-month follow-up, 11 of the 15 participants initially 
considered responsive to treatment continued to demonstrate a 50% or greater 
reduction in symptoms, that is, 65% of the total sample were classified as 
responsive 1 month posttreatment. The 4 participants who were initially 
considered responsive to treatment but no longer responsive at 1 month follow-
up all had scores within the moderate depression range. Two of the 15 
individuals initially responsive to treatment could be considered to be relapsing, 
defined by Prudic et al. (2004) as an increase in HAM-D scores of at least 10 
points from posttreatment to follow-up and a total HAM-D score greater than 16. 
According to this definition, 13% of the participants in the current study would 
be considered to have relapsed. Further, the current findings showed that 11.8% 
of those receiving bifrontal ECT, or 2 participants, were completely 
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nonresponsive to treatment.  
In terms of participant mean scores across treatment, average HAM-D 
scores prior to treatment fell within the severe depression range (M=37.18, 
SD=8.76). At posttreatment, an average reduction in HAM-D scores of over 70% 
was observed (M=10.12, SD=9.60) with the mean score falling in the mild 
depression range. At 1 month follow-up average HAM-D scores increased slightly 
but still reflected over a 50% reduction in scores from the pretreatment baseline 
HAM-D measures (M=15.12, SD=9.45) with the mean continuing to fall in the 
mild depression range.  
Data analyzed using a repeated measures ANOVA compared mean 
participant HAM-D scores from pretreatment, posttreatment, and follow-up 
testing and results are illustrated in Figure 1. Mauchly’s test showed that the 
assumption of sphericity had been violated (ω=.558, p <.05); therefore, the 
degrees of freedom were corrected using the Greenhouse-Geisser correction. 
Results of this test revealed that the level of participant depression differed 
significantly at the three interview administrations, F (1.39,22.20) = 58.209, p < 
.05, ηp2 = 0.784. Post-hoc comparisons using the Bonferroni adjustment for 
significance indicated that the average HAM-D scores were significantly lower at 
posttreatment (10.12 ± 9.60) and follow-up (15.12 ± 9.453) compared to 
pretreatment (37.18 ± 8.76) with statistical significance for both comparisons (p 































Figure 1.  Group Comparison of Mean Scores on the HAM-D 
 
* HAM-D values are classified as follows: 0-9 insignificant levels of depression, 10-19 mild depression, 
20-29 moderate depression, >30 severe depression  
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reduction in participant report of depression from pretreatment to posttreatment 
(immediately following treatment and 1 month later).  Post-hoc comparisons, on 
the other hand, showed an increase in participant report of depression on the 
HAM-D from posttreatment (10.12 ± 9.60) to follow-up (15.12 ± 9.45), findings 
that were statistically significant at the p < .05 level. These results show that, on 
average, participants’ depressive symptoms increased from posttreatment levels 
by follow-up, that is, 1 month later; however, the mean level of depression at 
the time of follow-up was still significantly lower than the mean level prior to 
treatment. Two of the 15 participants (or 13.4%) who were initially considered 
to be responsive to treatment, however, were considered to have relapsed 1 
month following the cessation of treatment, that is, had a 10-point or more 
increase in HAM-D scores, and a score at or above a 16 from posttreatment to 
follow-up. 
Research Question 2 
Do participants treated with bifrontal ECT display difficulties with 
retrograde and anterograde amnesia immediately posttreatment and at 1-month 
follow-up?  This research question examined whether participants receiving 
bifrontal ECT treatment had retrograde amnesia, that is, had difficulty 
remembering information they knew prior to treatment, or anterograde amnesia; 
that is, difficulty remembering newly learned information. Data from the 
Autobiographical Memory Interview – Short Form, WMS-III Logical Memory I and 
II, and Hopkins Verbal Learning Test were used to analyze this question. 
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Comparisons of participant performance on the measures of both retrograde and 
anterograde memory can be found in Figure 2. 
The Autobiographical Memory Interview – Short Form (AMI) represents 
the main measures of retrograde amnesia in the present study. Table 5 shows 
the means and standards deviations for the AMI. 
A repeated measures ANOVA compared mean AMI scores from 
pretreatment, posttreatment, and follow-up to determine if there were any 
changes in autobiographical memory recall between the three performances. 
Results of the ANOVA demonstrated that AMI scores differed significantly across 
the three test administrations, F (2,32) = 32.87, p < .05, ηp2 = 0.673. Post-hoc 
comparisons analyses using the Bonferroni adjustment for significance indicated 
that the average AMI scores were significantly lower at posttreatment (72.43 ± 
17.93) and follow-up (68.74 ± 20.88) when compared to pretreatment AMI 
scores (100 ± 0.00), yielding statistically significant results for both comparisons 
(p < .05). Findings of significant retrograde amnesia immediately following ECT 
treatment and 1 month later are not unexpected, even with bifrontal electrode 
placement. This is a common finding in ECT studies, that is, ECT treatment can 
negatively impact a person’s ability to remember past events long after the 
cessation of treatment (Kellner et al., 2010; McElhiney et al., 1997; Sackeim et 
al., 2007). In terms of anterograde amnesia, or the ability to recall newly learned 
information, several measures were used for assessment. The WMS-III Logical 
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Figure 2.  Group Comparison of Mean Scores on Measures  
of Anterograde and Retrograde Amnesia 
 
* AMI scores are graphed on the secondary Y-axis; LMI & II scores were converted from scaled scores to 





Means and Standard Deviations at Pretreatment, Posttreatment, and Follow-up 
for the Autobiographical Memory Interview – Short Form (AMI-SF) 
 Pretreatment Posttreatment Follow-up 






100 (0) 72.43 (17.93) 68.74 (20.88) 
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delayed condition (LMII, given after a 25-minute time delay). Table 6 shows the 
means and standard deviations from the two Logical Memory tests. 
A repeated measures ANOVA which compared mean scores for the 
immediate Logical Memory Test across treatment did not demonstrate a main 
effect for bifrontal ECT. In other words, there were no statistically significant 
changes in participants’ immediate recall of a story between pretreatment, 
posttreatment, and follow-up testing.  
Similarly, a repeated measures ANOVA for the delayed Logical Memory 
Test did not show a main effect for the treatment, suggesting that on average 
there were no significant changes in participants’ delayed story memory between 
pretreatment, posttreatment, and follow-up testing. 
The Hopkins Verbal Learning Test – Revised (HVLT), an auditory word list-
learning task, has both an immediate (HVLT Recall) and a delayed condition 
(HVLT Delayed, given after a 20-minute time delay). The means and standard 
deviations of the HVLT-R immediate and delayed memory conditions can be 
found in Table 7. 
A repeated measures ANOVA compared the mean scores between 
pretreatment, posttreatment, and follow-up testing for the HVLT Recall test and 
results are depicted above in Figure 2. The analysis revealed that participant 
average HVLT Recall test scores differed significantly between testing time 
points, F (2,32) = 10.63, p < .05, ηp2 = 0.399. Post-hoc comparisons analyses 






Means and Standard Deviations at Pretreatment, Posttreatment, and Follow-up 
for the WMS-III Logical Memory I and II (LMI & LMII) Tests 
 Pretreatment Posttreatment Follow-up 
    
Mean Logical Memory I 
Score (Standard Deviation) 9.25 (2.57) 8.81 (3.60) 10.69 (3.01) 
    
Mean Logical Memory II 
Score (Standard Deviation) 10.40 (2.67) 9.00 (4.99) 10.60 (2.13) 





Means and Standard Deviations at Pretreatment, Posttreatment, and Follow-up 
for the Hopkins Verbal Learning Test-Revised (HVLT-R) 
 Pretreatment Posttreatment Follow-up 
    
Mean HVLT-R 
Immediate Recall Score 
(Standard Deviation) 
43.65 (13.37) 39.94 (14.16) 49.65 (11.77) 
    
Mean HVLT-R 
Delayed Recall Score 
(Standard Deviation) 
42.25 (13.74) 38.94 (14.00) 49.75 (10.22) 
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Recall scores were significantly higher at follow-up (49.65 ± 11.78) compared to 
both mean pretreatment scores (43.65 ± 13.37) and mean posttreatment scores 
(39.94 ± 14.17), with both comparisons demonstrating statistical significance (p  
< .05).  Yet no significant difference was found between the mean pretreatment 
HVLT Recall scores (43.65 ± 13.369) and posttreatment scores (39.94 ± 
14.166). These results demonstrate improvement in participants’ immediate 
verbal list recall performance at 1-month follow-up compared to pre- and 
posttreatment performance, but fail to demonstrate that bifrontal ECT caused 
impairment in immediate anterograde word list memory. 
For the results of the delayed word list-learning memory test, a repeated 
measures ANOVA compared participant mean scores on the HVLT Delayed test 
across the three test administrations. Results of the ANOVA, seen above in 
Figure 2, revealed that participants’ average HVLT Delayed scores differed 
significantly across the three test sessions, F (2,30) = 11.455, p < .05, ηp2 = 
0.433. Post-hoc analyses using the Bonferroni adjustment for significance 
indicated that the average HVLT-R Delayed scores were significantly higher at 
follow-up (49.75 ± 10.22) than the average scores prior to treatment (42.25 ± 
13.73) and immediately after (42.25 ± 13.73). Pre- and posttreatment 
comparisons with follow-up scores showed statistically significant findings (p < 
.05). This is similar to the results from the HVLT Recall condition, which 
demonstrated that performance on average at follow-up was significantly 
improved from the performance pre and posttreatment. As with the immediate 
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condition, no statistically significant findings in terms of differences between the 
pre (42.25 ± 13.73) and posttreatment (42.25 ± 13.73) mean test scores, 
however, were shown indicating a lack of evidence that bifrontal ECT resulted in 
any impairments in delayed recall of a previously presented list of words 
repeatedly presented 25 minutes earlier. 
 
Research Question 3 
What are the effects of bifrontal ECT on participants’ performance on 
measures of executive functioning immediately posttreatment and at 1-month 
follow-up?  To address the question of the impact of bifrontal ECT on measures 
of executive functions, scores from the FAS verbal fluency test and several 
measures from the Behavioral Dyscontrol – Electronic Version were analyzed 
with repeated measures ANOVAs.  
Table 8 displays the means and standard deviations from the FAS Verbal 
Fluency Test.  As seen in Figure 3, the repeated measures ANOVA comparing 
mean FAS test scores among pretreatment, posttreatment, and follow-up 
revealed significant differences between the mean scores for the three 
administrations, F (2,32) = 18.541, p < .05, ηp2 = 0.537. Post-hoc comparisons 
analyses using the Bonferroni adjustment for significance indicated that the 
average FAS scores were statistically significantly lower at posttreatment (5.59 ± 
3.74) compared to pretreatment (9.88 ± 2.78, p < .05) and follow-up (9.41 ± 
3.26, p < .05), but found no statistically significant differences between the 




Means and Standard Deviations at Pretreatment, Posttreatment, 
and Follow-up for the FAS test 
 Pretreatment Posttreatment Follow-up 
    
Mean FAS Scores 
(Standard Deviation) 9.88 (2.78) 5.59 (3.74) 9.41 (3.26) 


























FAS Verbal Fluency Test
 
 
Figure 3.  Group Comparison of Mean Scores 
from the FAS Verbal Fluency Test 
 
* Average scaled scores range from 7-13 (standard deviation = 3) 
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(9.41 ± 3.26).  This data pattern showed that, on average, there were significant 
reductions in verbal fluency scores immediately posttreatment; however, by the 
time of follow-up 1 month later, participant performance had, on average, 
returned to baseline. The findings indicate that in terms of verbal fluency, any 
negative side effects that occurred as a result of treatment appeared to be 
transient. 
Results of the Alphanumeric sequencing test from the Behavioral 
Dyscontrol Scale – Electronic Version (BDS-EV) were used to evaluate the 
following components of executive functions: cognitive flexibility, information 
processing speed, visual scanning ability, integration of visual and motor 
functions, sequencing, and the ability to shift train of thought. Table 9 reports 
the means and standard deviations from the raw scores for total time to 
complete the Alphanumeric sequencing task. 
As seen in Figure 4, a repeated measures ANOVA that compared 
participants’ mean completion times on the Alphanumeric sequencing task across 
the three administrations did not indicate any differences in performance on this 
task between pretreatment, posttreatment, and follow-up. That is, there were no 
statistically significant changes in mean scores between pretreatment, 
posttreatment, and follow-up testing on this task.  Total response time (the time 
it takes to formulate and execute a response) on the Simple choice reaction time 
(SCRT) tasks from the BDS-EV, was used to capture aspects of attention, motor 




Means and Standard Deviations at Pretreatment, Posttreatment, and 
Follow-up for the Alphanumeric Sequencing (ANS) Task 
 Pretreatment Posttreatment Follow-up 
    
Mean ANS Completion 

















































































Alphanumeric Sequencing Test Simple Choice Reaction Time Test
 
 
Figure 4.  Group Comparison of Mean or Median Scores from the Alphanumeric 
Sequencing and Simple Choice Reaction Time Tasks 
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participant median total response time was calculated for the SCRT trials. Table 
10 shows the means and standard deviations for participants’ median total 
response time on the SCRT. 
A repeated measures ANOVA, also illustrated in Figure 4, which compared 
the means for total response time per trial between pretreatment, posttreatment, 
and follow-up testing for the SCRT task, did not indicate a main effect of the 
treatment. There were no statistically significant differences in mean scores 
between pretreatment, posttreatment, and follow-up testing on this task 
suggesting that bifrontal ECT treatment did not result in changes in participant 
performance on average for this task. 
The total number of errors from the Branching Go-No-Go (BGNG) task 
from the BDS-EV were analyzed to provide a measure of impulsivity in 
responding, another executive function thought to be mediated by frontal lobe 
activity. Table 11 reports the means and standard deviations for participants’ 
total errors on the BGNG task. 
As seen is Figure 5, a repeated measures ANOVA compared participants’ 
mean total errors between pretreatment, posttreatment, and follow-up testing 
administrations and revealed that average errors differed significantly between 
the three test administrations, F (2,26) = 5.423, p < .05, ηp2 = 0.294. Post-hoc 
analyses using the Bonferroni adjustment for significance indicated that the 
average number of errors on the BGNG task was statistically significantly lower at 






Means and Standard Deviations at Pretreatment, Posttreatment, and 
Follow-up for the Simple Choice Reaction Time (SCRT) Task 
 Pretreatment Posttreatment Follow-up 
    
Mean SCRT Total 
Time in Milliseconds 
(Standard Deviation) 
828.21 (205.86) 910.68 (193.70) 787.50 (123.10) 






Means and Standard Deviations at Pretreatment, Posttreatment, and 
Follow-up for the Branching Go No Go (BGNG) Task 
 Pretreatment Posttreatment Follow-up 
    
Mean Errors for 
BGNG Task 
(Standard Deviation) 
3.14 (3.21) 2.36 (3.10) 1.29 (1.20) 





























Branching Go No Go
 
 
Figure 5.  Group Comparison of Mean Errors  
Made on the Branching Go-No-Go Task 
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Comparisons failed to demonstrate statistically significant differences between 
the mean number of errors made at pre- (3.14 ± 3.21) versus posttreatment 
(2.36 ± 3.10) or between posttreatment (2.36 ± 3.10) and follow-up (1.29 ± 
1.20). This pattern of results suggests that participants displayed significantly 
less impulsivity in responding at follow-up compared to measures taken at 
baseline. From these results, we can conclude that the treatment resulted in an 
improvement in participants’ ability to inhibit responding over the course of 
treatment. 
 
Research Question 4 
What are the effects of bifrontal ECT on participants’ performance on 
measures of processing speed immediately posttreatment and at 1-month follow-
up?  To address this question regarding the impact of bifrontal ECT on measures 
of processing speed, the Processing Speed Index (PSI) scores (derived from the 
combination of the WAIS-III subtests of Digit-Symbol Coding and Symbol 
Search) were analyzed. Table 12 shows the means and standard deviations from 
the PSI. 
As shown in Figure 6, a repeated measures ANOVA compared the mean 
participant PSI scores between pretreatment, posttreatment, and follow-up test 
administrations and revealed differences between the scores at the three test 
sessions, F (2,30) = 7.854, p < .05, ηp2 = 0.344. Post-hoc analyses using the 
Bonferroni adjustment for significance indicated that the average PSI scores 





Means and Standard Deviations at Pretreatment, Posttreatment, 
and Follow-up for the Processing Speed Index (PSI) 
 Pretreatment Posttreatment Follow-up 
    
Mean PSI Scores 
(Standard Deviation) 91.06 (15.14) 85.13 (10.76) 95.81 (12.92) 





























Figure 6.  Group Comparison of Mean Scores on the Processing Speed Index 
 
* Average standard scores range from 85-115 (standard deviation = 15) 
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(85.13 ±10.76, p < .05). Mean PSI scores decreased slightly from pretreatment 
(91.06 ± 15.14) to posttreatment (85.13 ±10.76), although this was not 
statistically significant. There was also no difference found between pretreatment 
PSI means (91.06 ± 15.14) and follow-up (95.81 ± 12.92). This pattern of 
results failed to demonstrate any ill effects of bifrontal ECT on processing speed, 
but instead, similar to measures of anterograde memory and impulsivity, 
suggests that participants displayed marked improvements in processing speed 
at 1-month follow-up. 
 
Supplementary Analyses 
The Mini-Mental Status Exam (MMSE) was administered to provide a 
direct comparison with previous bifrontal studies that relied solely on this test as 
their dependent measure of cognitive function. In the current study, results of a 
repeated measures ANOVA on the MMSE raw scores failed to show a main effect 
for cognitive change from bifrontal ECT treatment. This finding is consistent with 
those from several previous studies that demonstrated a lack of effect of 
bifrontal ECT on cognitive status (e.g., Bailine et al., 2000; Eschweiler et al., 
2002; Heikman et al., 2002; Kellner et al., 2010; Ranjkesh et al., 2000; Schulze-
Rauschenbach et al., 2005). 
In an effort to capture participants’ subjective opinions regarding memory 
functions across treatment, participants were given the opportunity to rate their 
memory ability before treatment was provided and after treatment (i.e., 
immediately following treatment and at the 1-month follow-up. Self-assessment 
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of memory functioning was done using a scale of 1 to 7, with 1 reflecting no 
perceived memory disturbances and 7 reflecting severe memory difficulties. Ten 
participants completed the subjective memory question at pretreatment and 
follow-up and 9 completed it immediately posttreatment. At pretreatment, the 
mean subjective memory rating was 3, with a range of scores from 1 to 5. 
Immediately posttreatment scores ranged from 1 to 6 with a mean of 3.45. At 
follow-up the mean rating was 4.6, with scores ranging from 2 to 7. Analyses of 
these results suggest that participants already perceived mild memory difficulties 
prior to treatment which did not change drastically at posttreatment, but by 
follow-up on average participants reported a slight increase in memory problems. 
Although not statistically significant, the results approach significance (t (8) = - 
2.229, p = .056), suggesting that participants demonstrated a trend toward 
reporting significantly greater problems with their memory by 1-month follow-up. 
These findings are consistent with previous findings of subjective memory 
complaints that persist even several months posttreatment (Squire & Slater, 
1983). 
Participants were also asked to rate how effective they considered 
bifrontal ECT in treating their depression. On a scale of 1 to 7, with 1 being 
completely ineffective and 7 being completely effective, the sample yielded an 
average effectiveness rating of 4.40 (SD=2.17). This suggests that, on average, 
the 10 participants who rated the effectiveness of bifrontal ECT considered it 
moderately effective. However, the scores ranged from 1 to 7, demonstrating 
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considerable difference in the perception of treatment effectiveness.  A 
correlational analysis demonstrated a significant negative correlation between 
participants’ ratings of the effectiveness of the ECT treatment and their HAM-D 
scores at follow-up (r(8)=-.715, p<.05). This suggests that as participants’ levels 
of depressive symptoms rose their opinion of the effectiveness of their treatment 
decreased. 
Finally, to determine necessary sample sizes to detect effects on the 
measures that did not yield significant ANOVA results power analyses were 
conducted. A power of .8 (80% probability of rejecting a false null) was used. For 
the MMSE, results of the power analysis suggested 1,313 participants would have 
been necessary to detect effects. Concerning the Logical Memory I and II tests 
power analyses revealed sample sizes of 141 and 41 participants, respectively, 
would have been necessary. Last, for the computer-administered tests, SCRT and 
ANS, power analyses suggested sample sizes of 50 and 62 would have been 
necessary to detect effects. Therefore, results suggest that participant sample 
sizes much larger than the 30 would have been necessary to detect effects. 
Small effect sizes rather than insufficient sample size may be to blame for the 




This study set out to examine the clinical efficacy and potential cognitive 
side effects of bifrontal ECT, an ECT variation that has received far less attention 
in the literature than bitemporal or right unilateral procedures. Further, the study 
aimed to compare current findings to those of previous research on other forms 
of ECT. Embedded in this effort is the concern that the mental cost (or side 
effects) of ECT may outweigh its potential benefits, especially if the treatment 
itself were to result in side effects that served to worsen or exacerbate an 
individual’s depressive symptomatology. ECT research has long debated the 
risk/benefit ratio of electroconvulsive treatment and some have proposed that 
bifrontal ECT may result in a more favorable ratio (Heikman et al., 2002). Further, 
all ECT research shares the common goals of providing detailed specific 
information to potential patients concerning expected outcomes, both negative 
and positive, as well as informing decisions in clinical practice. Despite its 
limitations, which will be discussed below, this study represents a significant 
contribution to this discussion and builds upon the current empirical knowledge 
base concerning bifrontal ECT. 
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Major Research Findings 
 
Treating Depression with Bifrontal ECT  
 Results of the present study indicate that bifrontal ECT is as effective a 
treatment of severe depression as other forms of ECT, and may have fewer side 
effects. The study showed that 88% of the participants responded immediately 
after completion of a standard series of bifrontal ECT, a rate that is comparable 
to the 70 to 90% response rate for all types of ECT reported by the American 
Psychiatric Association’s (2010) practice guidelines regarding treatment for 
depression, and higher than remission rates of 55% and 64% found in multisite 
research consortium projects (Kellner et al., 2006; Sackeim et al., 2001). Clearly, 
bifrontal ECT can be considered an effective course of action for severe, 
medication-resistant, depressive conditions. 
Like other investigations, the current study also found that a number of 
participants experienced a significant return of depressive symptoms 1 month 
after treatment cessation and that on average participants demonstrated an 
increasing trend in depression symptomatology from posttreatment to follow-up.  
Specifically, 13% of the participants who were shown to have a positive initial 
response (a 50% or more reduction in symptoms from pre- to posttreatment) 
were later classified as relapsed 1 month after the cessation of treatment, and all 
but 1 of the 15 participants initially considered responsive to treatment 
demonstrated an increase in their HAM-D scores from posttreatment to follow-up 
foreshadowing rising levels of depression. 
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Although the ideal goal is to prevent relapse, the 13% relapse rate found 
in this study is still relatively low compared to some other studies of ECT (such 
as Prudic et al., who reported a 64% 24-week relapse rate in their 2004 
publication and Grunhaus et al., who reported a 28.5% 3-month relapse rate in 
their 2001 study).  
The excitement that these data stir concerning very low relapse rates at 
follow-up must be tempered due to the lack of a longer follow-up period. This is 
considered a limitation of this study. The present data are restricted to only 1-
month follow-up which is much shorter than the follow-up periods of 24 weeks 
from Prudic et al. and 3 months in Grunhaus et al. This provides reason to be 
cautious in making strong conclusions about bifrontal ECT relapse rates. It is 
plausible that given the trend in the current sample of rising symptomatology 
longer follow-up periods may have resulted in a higher relapse rate. 
 
Effects of Bifrontal ECT on Memory 
 Memory loss and confusion represent the bulk of the complaints from 
individuals who have received ECT treatment (Malcolm, 1989; Squire & Slater, 
1983). In its inception, bifrontal electrode placement was hypothesized to spare 
memory functions because it avoids direct stimulation over the temporal lobes 
(Inglis, 1969). Prior to the current study, only two previous studies (Kellner et al., 
2010; Lawson et al., 1990) had attempted to assess memory functions in 
bifrontal ECT with targeted neuropsychological measures. 
 The present findings failed to corroborate the findings of Kellner et al. 
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(2010) concerning ill effects of bifrontal ECT on measures of verbal anterograde 
memory. Current results found no evidence of impaired anterograde memory on 
any of the measures administered, suggesting that bifrontal ECT did not result in 
impaired recall of newly learned information in this study. Specifically, concerning 
the ability to recall a story, no differences were found in participant performance 
between pretreatment, posttreatment, and follow-up. Further, contrary to the 
findings of Kellner et al. (2010), current results did not suggest impairment in 
immediate or delayed recall of information in learning a list of words. Rather, 
results of immediate and delayed tests of list learning were suggestive of 
average improvement at follow-up testing over pre and posttreatment 
performance. A possible interpretation of these results is that the relief of 
depression resulted in improved verbal memory functions by follow-up, while an 
alternative consideration is that the improvement is attributable to practice 
effects from repeated exposure to the list of words. The lack of alternative test 
forms is considered another limitation of the current study.  
Unfortunately, like previous ECT findings (Kellner et al., 2010; Sackeim et 
al., 2007) the current study showed persistent problems with retrograde 
amnesia. Whether retrograde amnesia will persist beyond 1 month is unclear; 
however, data from other investigations, including that of Sackeim et al. (2007), 
suggest that by 6 months posttreatment, there may be substantial improvement 
in the ability to remember autobiographical information.   
In this study, the results of the Autobiographical Memory Interview 
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revealed that bifrontal ECT had a significant impact on the accuracy of 
participants’ memories of previously recalled personally relevant information. On 
average, participants remembered only 72% of the information provided at 
pretreatment interviews immediately following the completion of their series of 
ECT treatments. At 1-month follow-up they remembered 69%. Contrary to 
findings that ECT does not produce cognitive effects that persist after treatment 
cessation (Lawson et al., 1990) and the hypothesis that bifrontal ECT may spare 
memory functions (Inglis, 1969) these results suggest that memory of personally 
relevant biographical information is significantly compromised with bifrontal ECT 
treatment and persists at least 1 month posttreatment. These findings are 
consistent with those of Kellner et al. (2010) who demonstrated that all three 
electrode placements caused impairment on this measure. Kellner et al. further 
demonstrated that bifrontal ECT caused a slightly greater disturbance in 
autobiographical memory than bitemporal or right unilateral electrode placement. 
Specifically, Kellner et al. found that participants who received bifrontal ECT 
could remember only 58% of the information provided on the AMI at baseline, 
whereas the current study found average recall on the AMI of 72% immediately 
posttreatment. Therefore, the current results suggest slightly less impairment in 
retrograde amnesia for bifrontal ECT compared to Kellner et al. Findings by 
Kellner et al. of 69 and 67% retrograde amnesia scores for the right unilateral 
and bitemporal groups are more consistent with present findings. When 
integrated with the current results this suggests that retrograde amnesia levels 
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are quite similar across the three electrode placements. 
Again, a lack of longer follow-up testing presents a limitation in 
interpreting this study’s retrograde amnesia data. It remains unknown whether 
retrograde amnesia would persist indefinitely or would dissipate after more time. 
Another limitation is that the AMI represents an imperfect measure of 
retrograde amnesia. For example, if participants offer inaccurate or vague 
memories during the pretreatment interview, that can confound their accuracy of 
recall at posttreatment and follow-up. Even though participants were encouraged 
to offer only clear and accurate memories, there was no mechanism to check 
accuracy. Since depression itself is believed to negatively affect memory and 
cognition (Calev et al., 1995), pretreatment responses could already be 
comprised by participants’ depressed states. The accuracy of the measure could 
be improved by consulting with participants’ families and friends to corroborate 
baseline responses, although if the individual has encoded the memory 
inaccurately, efforts to corroborate responses may confound the issue further. 
That said, the AMI is the most widely used measure of retrograde memory 
employed in ECT research. It likely represents the only standardized approach to 
measuring the autobiographical memory loss, which has long been a complaint 
of those who have completed ECT treatment (Rose et al., 2003). 
 Clearly, the current data and data from more recent studies of bifrontal 
ECT (Kellner et al., 2010), strongly suggest that this electrode placement does 
not spare all memory functions as was initially predicted (Inglis, 1969). Yet there 
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is no evidence, from current results, that bifrontal ECT causes greater memory 
impairment than alternative electrode placements. 
 
 Effects of Bifrontal ECT on Executive Functions 
 Executive functions refer to an individual’s ability to plan, execute, 
generate, organize, inhibit, and modify goal directed behavior. These functions 
are predominantly controlled by the frontal lobe of the brain, the area where 
bifrontal ECT provides direct stimulation. Therefore, answering the question of 
whether bifrontal ECT causes impairment in executive functions is possibly the 
most important and novel contribution of this study. It provides one of the most 
thorough examinations to date of frontal lobe functions in ECT treatment. 
 The FAS verbal fluency test measures an individual’s ability to generate 
verbal responses upon cueing under a time constraint. Results from this study 
are consistent with the findings from Calev et al. (1995) that bitemporal, right 
unilateral, and in this case bifrontal ECT, all result in impaired verbal fluency, 
although the ill effects of the treatment appear short-lived. Specifically, this 
study’s participants generated significantly more words at pretreatment and 
follow-up than at posttreatment. Immediately posttreatment, mean scores on the 
FAS test fell from the average range to well below average (5th percentile), 
suggesting considerable functional impairment immediately posttreatment.  On 
the positive side, mean scores returned to the average range by follow-up. This 
robust finding suggests that individuals undergoing bifrontal ECT may have 
clinically significant difficulty with verbal fluency and the generation of verbal 
80 
 
responses immediately following their treatment, but are likely to recover from 
these ill effects rather quickly. While Kellner et al. (2010) found no differences 
between the three electrode placements in letter or category fluency, their 
published data indicate that all three electrode placements resulted in 
comparable deterioration in category and word fluency as was found in this 
study. 
 Several computer-administered measures from the Behavioral Dystcontrol 
Scale – Electronic Version were employed to assess executive functions. The 
Alphanumeric sequencing (ANS) task is comparable to the popular Trails B task, a 
neuropsychological measure given in a paper-pencil format in several studies 
reviewed above (Kellner et al., 2010; Shulze-Rauschenbach et al., 2005). These 
tasks are considered measurements of cognitive flexibility, information 
processing speed, visual scanning ability, integration of visual and motor 
functions, sequencing, and the ability to maintain two different trains of thought. 
The unit of analysis for the ANS task was the total time participants took to 
complete the task. No differences were found in participants’ performance speed 
between pretreatment, posttreatment, and follow-up assessments. This suggests 
no impact of bifrontal ECT on the performance of this task, consistent with the 
findings from Kellner et al. (2010). Interestingly, data from Kellner et al. 
demonstrated a trend toward improvement in completion speed for Trails B for all 
three electrode placements from pre- to posttreatment testing. Again, this 
improvement could be attributable to practice effects. Yet, despite repeated 
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exposure to the tasks in this study, no significant improvement between the 
three administrations was observed. 
 Total response time (a combination of decision and movement time) from 
the Simple choice reaction time (SCRT) task of the BDS-EV was used to capture 
aspects of attention, motor planning, and motoric speed, all considered executive 
functions. Decision speed refers to the time between the presentation of the 
stimulus on the screen and the point when the individual lifts his or her finger 
from the button indicating they have made a choice. Movement time captures 
the time elapsed between lifting their finger from the button and hitting the 
button corresponding to their choice. By analyzing these variables, we can get a 
sense for how long an individual takes to generate an answer, create a motor 
plan, and execute the movement. In this analysis, no impact of the treatment 
was observed. This was consistent with findings from Sackeim et al. (2007) who 
found no ill effects of bitemporal or right unilateral ECT on measures of simple 
reaction time. 
 Finally, errors from the Branching Go-No-Go task were analyzed to 
capture aspects of impulsivity versus inhibition in responding. This is an 
important aspect of executive functioning that previous studies have not 
addressed. In the present case, results suggested that impulsivity and inhibition 
improved as a result of treatment, as follow-up error scores were significantly 
lower than pretreatment error scores. This improvement could be hypothesized 
to result from the relief of depression, but the issue of practice effects must 
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again be considered. Participants completed the same task three times, which 
may have allowed for adjustment to the task demands from pretreatment to 
follow-up assessment administrations. Nevertheless, current results lack evidence 
that bifrontal ECT causes impairment in inhibition or impulsivity. 
 To summarize, it does appear that verbal fluency is adversely affected 
immediately following bifrontal ECT. Any ill effects appear to diminish quickly, 
and do not appear to impact functioning long-term. All other areas of executive 
function appear unaffected by bifrontal ECT treatment. These findings are 
consistent with those of Kellner et al. (2010), which suggested no disadvantage 
of bifrontal ECT on measures of executive functions when compared to other 
electrode placements. This is an extremely important finding, considering the 
hypothesis that executive functions could be adversely affected by bifrontal ECT. 
 
Participant Experience with Bifrontal ECT 
 Historically, a challenge of ECT research has been to quantify subjective 
memory complaints of ECT patients. The current study employed a subjective 
question to target just this issue. In keeping with the findings of Squire and 
Slater (1983), current results suggested that individuals treated with bifrontal 
ECT tend to experience negative effects on memory that standardized measures 
often fail to capture. In this study, participants rated their memory as worse at 
follow-up than at pre- or posttreatment. Mean ratings rose from the low to the 
middle range of a seven-point subjective scale assessing participant experience 
of memory impairment. Statistical analyses did not find significant differences in 
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participants’ average subjective memory ratings between any of the three testing 
sessions, but these results are still important in that they demonstrate a rising 
concern about memory functions across treatment. Further, they demonstrate 
that subjective complaints still exist and may contribute to the fear and stigma 
associated with ECT treatment. 
Participants were also asked to rate how effective they considered 
bifrontal ECT in treating their depression. Interestingly, participant responses 
ranged from completely ineffective (a rating of 1) to completely effective (a 
rating of 7) with the average falling in the moderately effective range and 
suggesting that participants differed significantly in their individual perceptions of 
treatment effectiveness. As would be predicted, there was a moderately strong 
negative correlation (r=-.715, p<.05) between effectiveness ratings and follow-
up HAM-D interview results such that participants experiencing more depressive 
symptoms at follow-up rated the effectiveness of ECT treatment lower. This 
speaks to a flaw in the design of the study, as this question appears to capture 
more about how the participant is feeling at the time of follow-up rather than the 
participant’s perception of ECT’s effectiveness across their entire treatment 
course. Future studies wishing to assess patient opinion about effectiveness may 
wish to capture this at posttreatment as well as follow-up, given that ECT 
appears to be more effective immediately following treatment compared to 
weeks or months after cessation.
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Specificity of Measures in ECT Research 
 The Mini-Mental Status Exam is the most commonly used cognitive 
measurement in ECT research, and has often served as the sole measure of 
cognitive effects in studies (Bailine et al., 2000; Eschweiler et al., 2007; Heikman 
et al., 2002; Ranjkesh, Barekatain, & Akuchakin, 2005). The MMSE was also 
included in the battery of tests given in the current study for purpose of 
comparison. Results demonstrated no significant changes in MMSE scores 
between pretreatment, posttreatment, and follow-up assessments. Interestingly, 
a power analysis set at level .8 showed that 1,313 participants would have been 
necessary to find significant effects with this measure. This suggests that the 
lack of significance in MMSE results is probably not the result of small sample 
size. Rather, it is more likely due to a miniscule effect, detection of which would 
require a very large sample. These results call into question the results of prior 
ECT studies that employed the MMSE as the only measure of cognitive 
functioning. Based solely on results from the MMSE, many studies have drawn 
sweeping conclusions about the effects of ECT on cognition.  
This finding serves to remind consumers of ECT research and those who 
design ECT studies of the importance of including comprehensive 
neuropsychological measures. Without comprehensive measures, such as those 
employed in the current study, conclusions about the cognitive side effects of 




Procedural Considerations and Limitations 
 A significant procedural consideration involves the lack of random 
assignment and a control group in this study. The failure to randomize 
participants and the resulting possibility of a self-selection bias for ECT over 
alternative treatments for depression may reduce the generalizability of the 
results. Inclusion of random assignment and comparison and control groups 
could increase the strength of future bifrontal ECT studies. 
The administration of maintenance ECT treatments to participants, 
although a common clinical practice following ECT treatment utilized to reduce 
relapse (Kellner et al., 2006; Sackeim et al., 2001), is also considered a minor 
limitation of this study. Following the completion of their standard series of 
bifrontal ECT, and during the time between the posttreatment and follow-up 
neuropsychological assessments, 8 of the 17 participants received maintenance 
ECT treatments. Four individuals received one maintenance treatment between 
posttreatment testing and follow-up, 3 received two maintenance treatments, 
and 1 individual received seven maintenance treatments between post and 
follow-up testing.  
Interestingly, the participant who received the largest number of 
maintenance treatments (seven) displayed the greatest reduction in AMI scores, 
recalling only 59% and 38% of initial AMI responses at posttreatment and 
follow-up. Similarly, at follow-up, this individual also displayed the lowest FAS 
verbal fluency score of all the participants. Otherwise, visual analyses of the 
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other measures appear to reflect the similar trends seen in the statistical 
analyses of the full study sample. These results, although based solely on visual 
analysis of one individual’s scores, could suggest a cumulative negative effect of 
ECT treatment on retrograde amnesia and verbal fluency, an area worthy of 
exploration in future ECT research. 
 Since nearly half the study participants received intervening maintenance 
ECT treatments, one could suspect that the scores at follow-up might have been 
adversely affected. However, since few measures demonstrated evidence of 
impairment, the effects of these maintenance treatments appear negligible. This 
strengthens the hypothesis that ECT causes few measurable changes in 
cognition. On the positive side, maintenance treatments are commonly used in 
clinical and community-based ECT programs (those conducted outside 
randomized controlled clinical trials), and their inclusion in this study provides an 
investigation of ECT treatment that better approximates common clinical 
practices and increases the generalizability of the results. 
 Clearly larger sample sizes are preferred, as they increase generalizability 
and may improve statistical power. The small sample size of 17 in this study 
represents a limitation. Yet, the majority of the test measures in the analyses 
revealed statistically significant ANOVA omnibus effects. Power analyses of those 
measures that failed to yield significant effects suggested small sample size was 
not to blame. Rather, the effects themselves appear miniscule, requiring very 
large sample sizes (as was discussed above with the MMSE) in order to detect 
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significant findings. Still, larger sample size would add more variability, which in 
turn strengths generalizability. 
  Another limitation of the current study involves the reliability of the 
administration of the HAM-D. In most ECT studies with larger samples, raters 
reached a sufficient level of reliability on the administration of the HAM-D, 
typically ranging from .8 to .9. In the current study, the main study psychiatrist 
initially administered the HAM-D. But after training by an independent 
psychiatrist, the primary investigator administered the majority of the HAM-D 
interviews. This was done to avoid bias, since the study psychiatrist had 
substantial prior knowledge of participants’ history and clinical presentation. 
When questions surfaced concerning HAM-D scoring, the primary investigator 
would consult with the study psychiatrist until they agreed on the rating. 
However, no HAM-D administrations were repeated to reach a specified level of 
reliability. 
A final limitation is the possibility of practice effects due to the lack of 
alternative forms for several test measures, including story memory, word list 
learning, verbal fluency, processing speed, and all computerized measures of 
executive functions. Kellner et al. (2010) did not use alternative forms either, yet 
their findings suggested that bifrontal ECT participants demonstrated 
anterograde amnesia for list learning despite repeated exposures to the same 
list. In the current study it is possible that increased competence due to practice 
effects may have masked possible impairment on these measures. When 
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possible, future bifrontal ECT studies should consider using alternative 
measurement forms to reduce the impact of practice effects and more clearly 
differentiate the effects of bifrontal ECT on cognition. 
 
Implications 
 Data from the current study contribute to the evidence base that 
examines the effectiveness of bifrontal ECT for treating severe unipolar and 
bipolar depression. The current study demonstrated much higher ECT 
responsiveness and lower relapse rate than previous studies conducted outside 
the context of randomized controlled clinical trials. These are extremely 
important findings, in that they establish bifrontal ECT as an equally effective 
treatment for severe depression as other electrode placements. Furthermore, 
these results are derived from an authentic clinical ECT treatment program, and 
despite a small sample size, conclusions may generalize to similar university-
based hospital treatment programs. 
Concerning cognitive side effects, the current data call into question the 
hypotheses that bifrontal ECT may result in impaired executive functions due to 
direct stimulation of the frontal lobes. This study provides a significant 
contribution to the very limited research base examining executive functioning 
with bifrontal ECT and suggests that executive functions may not be ill affected 
by bifrontal stimulation. Unfortunately, despite hypotheses that bifrontal ECT 
might spare memory functions because it avoids stimulation to the temporal 
lobes, current findings suggest that bifrontal ECT, like other electrode 
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placements, may cause impairment in retrograde autobiographical memory. 
Further, data show that bifrontal ECT likely results in significant difficulty with 
verbal fluency immediately posttreatment. Although this effect appears short-
lived, this may cause distress in individuals who receive bifrontal ECT. Yet, 
current findings failed to demonstrate any ill effects of bifrontal ECT on 
anterograde memory or in any other area of cognition.  
 
Future Research Directions 
Although participants in this study served as their own controls due to the 
repeated measures design, future research on bifrontal ECT may be 
strengthened by including control and comparison treatment groups and 
employing random assignment. Data from a nondepressed control group may 
prove helpful, specifically on the Autobiographical Memory Interview, to 
illuminate the extent to which inaccurate recall of events is due to the passage of 
time or the poor specificity of the measure itself. 
The current study represents a preliminary effort to determine the 
effectiveness and cognitive side effects of bifrontal ECT. It would be helpful if 
future studies build upon this work by extending follow-up timelines and 
repeating neuropsychological measures at intervals such as 6 months, 1 year, or 
2 years at follow-up. This would allow for an investigation of persistent 
retrograde amnesia after cessation of ECT treatment.  
Further, it might be helpful to conduct studies that compared bifrontal 
ECT with other treatments, including those that hold promise for more rapid 
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symptom reduction without cognitive side effects. Isoflurane anesthesia is one 
example of such a treatment.  A number of studies conducted in Europe found 
rapid antidepressant effects for repeated Isoflurane treatments without any 
cognitive side effects (Englehard, Carl, & Hartung, 1993; Langer, Neumark, 
Koinig et al., 1985; Langer et al., 1995). 
Concerning the neuropsychological test battery, future bifrontal ECT 
studies may wish to include measures of visual anterograde and retrograde 
memory. The investigation of memory problems following bifrontal ECT in this 
study was limited only to verbal memory, leaving questions about the nature of 
visual memory problems with bifrontal ECT. 
The distinction between efficacy in community ECT treatment programs 
versus those affiliated with ECT research programs has been emphasized in the 
literature. Specifically, the American Psychiatric Association (2010) reports much 
higher efficacy of ECT within the context of randomized controlled clinical trials 
(70-90%) than has been demonstrated in community settings (30-64%; Kellner 
et al., 2006; Prudic et al., 2004; Sackeim et al., 2001). Interestingly, the current 
study was conducted in a university-affiliated psychiatric hospital but outside the 
context of a randomized controlled clinical trial, yet demonstrated a remission 
rate of 88% immediately posttreatment. This highlights the need for thorough 
investigations of the variables that contribute to the efficacy of an ECT treatment 
program including physician/patient relationship, technical procedures, and 
electrode placement. Continued research in these areas could potentially improve 
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treatment outcomes in community hospital or clinic ECT programs and improve 
patient response in those settings. 
 
Conclusions 
These results help clarify to a great extent what patients can expect to 
experience following a treatment series with bifrontal ECT. In weighing the 
benefits versus the risks, these data strongly suggest the benefits are substantial 
in reducing the acute symptoms of depression while sparing cognition in most 
areas except autobiographical memory and immediate posttreatment verbal 
fluency.  
Clearly delineating for patients what the risks are concerning cognitive 
side effects of bifrontal ECT may assist medical providers and potential patients 
enter into more informed decisions about their care. Providing this knowledge 
upfront may serve to greatly reduce an individual’s anxiety and fear prior to 
bifrontal ECT treatment. Subsequently these results may help reduce the stigma 
of ECT, making it more likely to be utilized as a treatment option for severe, 


















Consent and Authorization Document 
Background 
You are being invited to take part in a research study conducted by researchers from the 
Departments of Psychiatry, Anesthesiology, Psychology and Neurology, University of 
Utah.  Before you decide if you want to participate, it is important for you to understand 
why the research is being done and what it will involve.  Please take time to read the 
following information carefully and discuss it with friends and relatives if you wish.  Ask 
us if there is anything that is not clear, or if you would like more information.  Take time 
to decide whether or not you want to volunteer to take part in this study. 
 
One of the standard medical treatments for moderate to severe clinical depression is 
Electroconvulsive Therapy (ECT), also known as “shock treatment”.  These ECT 
treatments are administered by physicians together with relaxant drugs and anesthetic 
medications and other therapeutic procedures as your physicians may in their judgment 
determine to be necessary or appropriate.  ECT treatments are usually repeated at 
intervals, usually every 2-3 days for about 2.5 to 3.5 weeks and about 8 total 
treatments.  In many cases, a series of ECT treatments leads to substantial 
improvement in symptoms of depression.  We are investigating whether symptoms of 
depression can be equally improved by a different course of treatments involving no 
shocks. Instead the patient is simply put deeply to sleep with the inhalant anesthetic, 
Isoflurane, for the same series of 8 treatment sessions over the same 2.5 to 3.5 weeks.  
We will also test whether the Isoflurane treatments may have less side effects than ECT 
in terms of temporary memory problems.  In other research studies, a small number of 
depressed patients have shown good results after Isoflurane anesthesia.  Your physician 
and the physicians involved in this study believe that you are an appropriate candidate 
for either ECT or Isoflurane treatments. 
 
Randomized and Blinded Trial 
This research project is designed to compare Isoflurane treatments vs. ECT treatments 
in 50 patients with depression.  In this initial Phase 1 of the study, 7-9 patients will be 
selected to  receive Isoflurane as their treatment type while another 7-9 will be assigned 
to receive ECT.  Before, during and after the treatments, you will have your depressive 
symptoms measured along with various aspects of memory and other cognitive 
functions. Some of the doctors involved will be blinded and they will not know which of 




Screening:  During screening, you will be asked questions about your health history, 
medication use, and current health issues, with specific attention to your depressive 
symptoms including any thoughts you might have of suicide or self harm.  We will also 
perform baseline or pretreatment tests of memory and mental function (total screening 
assessment time around 1 hour). 
 
Treatments:  Treatment procedures will take place at the University of Utah 
Neuropsychiatric Institute in the ECT Procedure Room.  Each session is expected to take 
between 1.5 and 2.5 hours.  If you are randomized to receive the standard ECT 
treatments, you will first be given the usual methohexital anesthesia and then a 
tourniquet will be placed around your wrist.  Other medications will be given to reduce 
any excessive muscle contractions and other possible effects of the ECT stimulus.  Then, 
the ECT stimulus will be administered and your physiological responses and vital signs 
will be monitored by your electroencephalogram (EEG), your electrocardiogram (ECG), 
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blood pressure, pulse oximetry and exhaled CO2 to assess your state of respiration and 
blood oxygen, anesthetic concentration, and by the evidence of muscle contraction in 
the hand with the tourniquet. 
If you receive the Isoflurane anesthesia treatments instead of ECT, methohexital 
anesthesia will first be given, followed by inhaled Isoflurane just sufficient to suppress 
bursts in the monitored EEG tracing for approximately 15 minutes, and then anesthetic 
will be discontinued.  Additional medications will be given to help reduce risk of nausea 
or vomiting.  The total time for each treatment session is expected to be about 1.5 to 
2.5 hours. 
Whether you are assigned to receive ECT or Isoflurane, the treatments will be repeated 
8 times over a 2.5 to 3.5 week period. 
 
Assessing Changes in Depressive Symptoms, Memory and Cognition 
The same tests of memory and mental function performed at baseline prior to the 
treatments will be repeated 12-24 hours after the 8th treatment and 4 weeks after the 
8th and final treatment.  Changes in severity of depressive symptoms will be assessed by 
a clinical interview before each of the 8 treatment sessions, as well as 24 hours after the 
last treatment session and at 4 weeks after the last treatment session.   
 
Risks:  ECT is a well established treatment procedure.  Under the current standard of 
practice the significant risks of ECT include: short and long term memory impairment, 
status epilepticus and complications from anesthesia including life-threatening cardiac 
arrhythmias, respiratory arrest, myocardial infarction, stroke and even death. The 
physicians involved in these procedures are experienced with ECT and will be closely 
monitoring responses to the ECT and all vital functions, and will take all appropriate 
steps to minimize these risks. 
Isoflurane is a standard anesthesia induction agent.  Its use has been shown to be 
effective in standard surgical care.  However, anesthesia carries the risk of complications 
including life-threatening cardiac arrhythmias, respiratory arrest, myocardial infarction, 
stroke and even death.  The physicians involved in these procedures are experienced 
with Isoflurane anesthesia and will be closely monitoring responses to the treatment and 
all vital functions, and will take all appropriate steps to minimize these risks. Additional 
use of an oropharyngeal or laryngeal mask airway may be considered as necessary to 
ensure safe ventilation.  Endotracheal intubation will be considered only as indicated by 
anesthetic pre-procedure evaluation and will be discussed with you prior to treatment.  
With the Isoflurane treatments, there is an additional risk that it may be ineffective in 
treating the patient’s psychiatric illness resulting in worsening depression and potential 
prolongation of the patient’s illness.  The physicians involved in the study will be 
monitoring depressive symptoms at frequent intervals, and will minimize this risk by 
stopping the Isoflurane treatments and switching to the standard ECT treatments if 
symptoms worsen significantly. 
REPRODUCTIVE RISKS 
While ECT is currently indicated for the treatment for some psychiatric illnesses during 
pregnancy, the effects of deep Isoflurane anesthesia on the embryo or fetus are 
currently unforeseeable.  It is possible that if the treatment is given to a pregnant 
woman it will harm the unborn child. Pregnant women must not take part in this study, 
nor should women who plan to become pregnant during the study. Women who are at 
risk of pregnancy will be asked to have a pregnancy test before taking part to exclude 
the possibility of pregnancy. If you could become pregnant you must use an effective 
contraceptive during the course of this study. Acceptable methods of birth control 
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include abstinence, oral contraceptives, the contraceptive patch, the contraceptive ring, 
condoms, etc.  If you become pregnant while taking part in the study, you must 
immediately tell your research doctor. Options will be discussed with you at that time. 
Whether or not you remain on study treatment, we will follow the outcome of your 
pregnancy and we will continue to follow you according to the study plan. 
 
Unforeseeable Risks 
In addition to the risks listed above, there may be risks which are currently unforeseen. 
 
Benefits: ECT is a well established treatment procedure with decades of proven benefit 
for treating serious psychiatric illness such as psychotic depression, mania and suicidal 
thoughts.  For many patients ECT is the most effective form of treatment for their illness 
and results in a return of mental health.  Isoflurane treatments have limited research 
showing efficacy equal to ECT in severe psychiatric illness.  However, if further studies 
demonstrate that Isoflurane is as effective as ECT in treating moderate to severe 
depression with less memory side effects, and no social stigma, it may offer depressed 
patients and their physicians a new treatment option that many might prefer.   
 
Alternative Procedures 
If you do not want to take part in the study, you may choose to not participate in this 
study. This will in no way affect the treatment you receive from your medical providers. 
 
Confidentiality 
We will keep all research records that identify you private to the extent allowed by law. 
Records about you will be kept locked in filing cabinets or on computers protected with 
passwords. Only those who work with this study will be allowed access to your 
information. However, representatives from the Food and Drug Administration, the 
National Institutes of Health and the National Alliance for Research on Schizophrenia and 
Affective Disorders (the sponsor) may inspect and/or copy the records that identify you. 
Results of the study may be published; however, your name and other identifying 
information will be kept private.  
 
Person to Contact 
If you have questions, complaints or concerns about this study, or if you think you may 
have been injured from being in this study,  you can contact Dr. Howard Weeks at 801-
583-2500. Dr. Weeks can be reached at this number 24 hours a day. 
 
Research Participant Advocate:  You may also contact the Research Participant Advocate 
(RPA) by phone at (801) 581-3803 or by email at participant.advocate@hsc.utah.edu. 
 
Institutional Review Board 
Contact the Institutional Review Board (IRB) if you have questions regarding your rights 
as a research participant. Also, contact the IRB if you have questions, complaints or 
concerns which you do not feel you can discuss with the investigator. The University of 
Utah IRB may be reached by phone at (801) 581-3655 or by e-mail at irb@hsc.utah.edu. 
 
Research Related Injury Section 
If you are injured from being in this study, medical care is available to you at the 
University of Utah, as it is to all sick or injured people. The University of Utah does not 
have a program to pay you if you are hurt or have other bad results from being in the 
study. The costs for any treatment or hospital care would be charged to you or your 
insurance company (if you have insurance), to the study sponsor or other third party (if 
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applicable), to the extent those parties are responsible for paying for medical care you 
receive. Since this is a research study, some health insurance plans may not pay for the 
costs.  
 
The University of Utah is a part of the government.  If you are injured in this study, and 
want to sue the University or the doctors, nurses, students, or other people who work 
for the University, special laws may apply.  The Utah Governmental Immunity Act is a 
law that controls when a person needs to bring a claim against the government, and 




It is up to you to decide whether or not to take part in this research.  If you do decide to 
take part you will be asked to sign this consent form. If you decide to take part you are 
still free to withdraw at any time and without giving a reason. This will not affect the 
relationship you have with the investigator or staff nor standard of care you receive. 
 
Unforeseeable Risks 
In addition to the risks listed above, there may be risks which are currently unforeseen. 
 
Right of Investigator to Withdraw 
You may withdraw from the study at any time without penalty. Dr. Weeks or Dr. Smith 
can withdraw you without your approval.  Possible reasons for investigator withdrawal 
include significant worsening of depressive symptoms or evidence of intolerance to the 
treatment. 
 
Costs to Participants and Compensation 
There are no costs to you or any compensation for any of the procedures described 
above.  However, if you are assigned to the conventional ECT treatment, and you have 
medical insurance coverage, we will bill your provider for these treatment costs in the 
ordinary manner.   
 
New Information: 
Sometimes new information about the topic being studied becomes available during a 
research project. If this happens, your research doctor will tell you about it so you can 
decide whether or not to continue. 
 
Number of Participants 
We expect about 50 people will be in this study. 
  
Authorization for Use of Your Protected Health Information 
Signing this document means you allow us, the researchers in this study, and others 
working with us to use information about your health for this research study.  You can 
choose whether or not you will participate in this research study.  However, in order to 
participate you have to sign this consent and authorization form. 
This is the information we will use: 
• Name, address, and telephone number 
• Medical history including psychiatric symptoms, current and past medications or 
therapies 
• Information from the memory testing 
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• Information on changes in your psychiatric symptoms that occur over the testing 
period 
 
Others who will have access to your information for this research project are the 
University’s Institutional Review Board (the committee that oversees research studying 
people) and authorized members of the University of Utah workforce who need the 
information to perform their duties (for example: to provide treatment, to ensure 
integrity of the research, and for accounting or billing matters). 
If we share your information with anyone outside the University of Utah Health Sciences 
you will not be identified by name, social security number, address, telephone number, 
or any other information that would directly identify you, unless required by law. 
You may revoke this authorization.  This must be done in writing.  You must either give 
your revocation in person to the Principal Investigator or the Principal Investigator’s 
staff, or mail it to: Dr. Howard Weeks 501 Chipeta Way, Salt Lake City, Utah 84108.  If 
you revoke this authorization, we will not be able to collect new information about you, 
and you will be withdrawn from the research study.  However, we can continue to use 
information we have already started to use in our research, as needed to maintain the 
integrity of the research.  This authorization lasts until this study is finished. 
 
Consent 
I confirm that I have read and understand this consent and authorization document and 
have had the opportunity to ask questions.  I understand that my participation is 
voluntary and that I am free to withdraw at any time, without giving any reason, without 
my medical care or legal rights being affected.  I will be given a signed copy of the 
consent and authorization form to keep.  
 
I agree to participate in this research study and authorize you to use and disclose health 





________________________     ____________ 
Participant’s Signature    Date 
 
____________________________________________ 
Name of Person Obtaining Authorization and Consent 
 
 
______________________________________________               __________ 




Consent and Authorization Document 
Background 
You are being invited to take part in a research study conducted by researchers from the 
Departments of Psychiatry, Anesthesiology, Psychology and Neurology, University of 
Utah.  Before you decide if you want to participate, it is important for you to understand 
why the research is being done and what it will involve.  Please take time to read the 
following information carefully and discuss it with friends and relatives if you wish.  Ask 
us if there is anything that is not clear, or if you would like more information.  Take time 
to decide whether or not you want to volunteer to take part in this study. 
 
One of the standard medical treatments for moderate to severe clinical depression is 
Electroconvulsive Therapy (ECT), also known as “shock treatment”.  These ECT 
treatments are administered by physicians together with relaxant drugs and anesthetic 
medications and other therapeutic procedures as your physicians may in their judgment 
determine to be necessary or appropriate.  ECT treatments are usually repeated at 
intervals, usually every 2-3 days for about 2.5 to 3.5 weeks and about 8 total 
treatments.  In many cases, a series of ECT treatments leads to substantial 
improvement in symptoms of depression.  We are investigating whether symptoms of 
depression can be equally improved by a different course of treatments involving no 
shocks. Instead the patient is simply put deeply to sleep with the inhalant anesthetic, 
Isoflurane, for the same series of 8 treatment sessions over the same 2.5 to 3.5 weeks.  
We will also test whether the Isoflurane treatments may have less side effects than ECT 
in terms of temporary memory problems.  In other research studies, a small number of 
depressed patients have shown good results after Isoflurane anesthesia.  Your physician 
and the physicians involved in this study believe that you are an appropriate candidate 
for either ECT or Isoflurane treatments. 
 
Randomized and Blinded Trial 
This research project is designed to compare Isoflurane treatments vs. ECT treatments 
in 50 patients with depression.  In this initial Phase 1 of the study, 7-9 patients will be 
selected to  receive Isoflurane as their treatment type while another 7-9 will be assigned 
to receive ECT.  Before, during and after the treatments, you will have your depressive 
symptoms measured along with various aspects of memory and other cognitive 
functions. Some of the doctors involved will be blinded and they will not know which of 




Screening:  During screening, you will be asked questions about your health history, 
medication use, and current health issues, with specific attention to your depressive 
symptoms including any thoughts you might have of suicide or self harm.  We will also 
perform baseline or pretreatment tests of memory and mental function (total screening 
assessment time around 1 hour). 
 
Treatments:  Treatment procedures will take place at the University of Utah 
Neuropsychiatric Institute in the ECT Procedure Room.  Each session is expected to take 
between 1.5 and 2.5 hours.  If you are randomized to receive the standard ECT 
treatments, you will first be given the usual methohexital anesthesia and then a 
tourniquet will be placed around your wrist.  Other medications will be given to reduce 
any excessive muscle contractions and other possible effects of the ECT stimulus.  Then, 
the ECT stimulus will be administered and your physiological responses and vital signs 
will be monitored by your electroencephalogram (EEG), your electrocardiogram (ECG), 
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blood pressure, pulse oximetry and exhaled CO2 to assess your state of respiration and 
blood oxygen, anesthetic concentration, and by the evidence of muscle contraction in 
the hand with the tourniquet. 
If you receive the Isoflurane anesthesia treatments instead of ECT, methohexital 
anesthesia will first be given, followed by inhaled Isoflurane just sufficient to suppress 
bursts in the monitored EEG tracing for approximately 15 minutes, and then anesthetic 
will be discontinued.  Additional medications will be given to help reduce risk of nausea 
or vomiting.  The total time for each treatment session is expected to be about 1.5 to 
2.5 hours. 
Whether you are assigned to receive ECT or Isoflurane, the treatments will be repeated 
8 times over a 2.5 to 3.5 week period. 
 
Assessing Changes in Depressive Symptoms, Memory and Cognition 
The same tests of memory and mental function performed at baseline prior to the 
treatments will be repeated 12-24 hours after the 8th treatment and 4 weeks after the 
8th and final treatment.  Changes in severity of depressive symptoms will be assessed by 
a clinical interview before each of the 8 treatment sessions, as well as 24 hours after the 
last treatment session and at 4 weeks after the last treatment session.   
 
Risks:  ECT is a well established treatment procedure.  Under the current standard of 
practice the significant risks of ECT include: short and long term memory impairment, 
status epilepticus and complications from anesthesia including life-threatening cardiac 
arrhythmias, respiratory arrest, myocardial infarction, stroke and even death. The 
physicians involved in these procedures are experienced with ECT and will be closely 
monitoring responses to the ECT and all vital functions, and will take all appropriate 
steps to minimize these risks. 
Isoflurane is a standard anesthesia induction agent.  Its use has been shown to be 
effective in standard surgical care.  However, anesthesia carries the risk of complications 
including life-threatening cardiac arrhythmias, respiratory arrest, myocardial infarction, 
stroke and even death.  The physicians involved in these procedures are experienced 
with Isoflurane anesthesia and will be closely monitoring responses to the treatment and 
all vital functions, and will take all appropriate steps to minimize these risks. Additional 
use of an oropharyngeal or laryngeal mask airway may be considered as necessary to 
ensure safe ventilation.  Endotracheal intubation will be considered only as indicated by 
anesthetic pre-procedure evaluation and will be discussed with you prior to treatment.  
With the Isoflurane treatments, there is an additional risk that it may be ineffective in 
treating the patient’s psychiatric illness resulting in worsening depression and potential 
prolongation of the patient’s illness.  The physicians involved in the study will be 
monitoring depressive symptoms at frequent intervals, and will minimize this risk by 
stopping the Isoflurane treatments and switching to the standard ECT treatments if 
symptoms worsen significantly. 
REPRODUCTIVE RISKS 
While ECT is currently indicated for the treatment for some psychiatric illnesses during 
pregnancy, the effects of deep Isoflurane anesthesia on the embryo or fetus are 
currently unforeseeable.  It is possible that if the treatment is given to a pregnant 
woman it will harm the unborn child. Pregnant women must not take part in this study, 
nor should women who plan to become pregnant during the study. Women who are at 
risk of pregnancy will be asked to have a pregnancy test before taking part to exclude 
the possibility of pregnancy. If you could become pregnant you must use an effective 
contraceptive during the course of this study. Acceptable methods of birth control 
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include abstinence, oral contraceptives, the contraceptive patch, the contraceptive ring, 
condoms, etc.  If you become pregnant while taking part in the study, you must 
immediately tell your research doctor. Options will be discussed with you at that time. 
Whether or not you remain on study treatment, we will follow the outcome of your 
pregnancy and we will continue to follow you according to the study plan. 
 
Unforeseeable Risks 
In addition to the risks listed above, there may be risks which are currently unforeseen. 
 
Benefits: ECT is a well established treatment procedure with decades of proven benefit 
for treating serious psychiatric illness such as psychotic depression, mania and suicidal 
thoughts.  For many patients ECT is the most effective form of treatment for their illness 
and results in a return of mental health.  Isoflurane treatments have limited research 
showing efficacy equal to ECT in severe psychiatric illness.  However, if further studies 
demonstrate that Isoflurane is as effective as ECT in treating moderate to severe 
depression with less memory side effects, and no social stigma, it may offer depressed 
patients and their physicians a new treatment option that many might prefer.   
 
Alternative Procedures 
If you do not want to take part in the study, you may choose to not participate in this 
study. This will in no way affect the treatment you receive from your medical providers. 
 
Confidentiality 
We will keep all research records that identify you private to the extent allowed by law. 
Records about you will be kept locked in filing cabinets or on computers protected with 
passwords. Only those who work with this study will be allowed access to your 
information. However, representatives from the Food and Drug Administration, the 
National Institutes of Health and the National Alliance for Research on Schizophrenia and 
Affective Disorders (the sponsor) may inspect and/or copy the records that identify you. 
Results of the study may be published; however, your name and other identifying 
information will be kept private.  
 
Person to Contact 
If you have questions, complaints or concerns about this study, or if you think you may 
have been injured from being in this study,  you can contact Dr. Howard Weeks at 801-
583-2500. Dr. Weeks can be reached at this number 24 hours a day. 
 
Research Participant Advocate:  You may also contact the Research Participant Advocate 
(RPA) by phone at (801) 581-3803 or by email at participant.advocate@hsc.utah.edu. 
 
Institutional Review Board 
Contact the Institutional Review Board (IRB) if you have questions regarding your rights 
as a research participant. Also, contact the IRB if you have questions, complaints or 
concerns which you do not feel you can discuss with the investigator. The University of 
Utah IRB may be reached by phone at (801) 581-3655 or by e-mail at irb@hsc.utah.edu. 
 
Research Related Injury Section 
If you are injured from being in this study, medical care is available to you at the 
University of Utah, as it is to all sick or injured people. The University of Utah does not 
have a program to pay you if you are hurt or have other bad results from being in the 
study. The costs for any treatment or hospital care would be charged to you or your 
insurance company (if you have insurance), to the study sponsor or other third party (if 
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applicable), to the extent those parties are responsible for paying for medical care you 
receive. Since this is a research study, some health insurance plans may not pay for the 
costs.  
 
The University of Utah is a part of the government.  If you are injured in this study, and 
want to sue the University or the doctors, nurses, students, or other people who work 
for the University, special laws may apply.  The Utah Governmental Immunity Act is a 
law that controls when a person needs to bring a claim against the government, and 




It is up to you to decide whether or not to take part in this research.  If you do decide to 
take part you will be asked to sign this consent form. If you decide to take part you are 
still free to withdraw at any time and without giving a reason. This will not affect the 
relationship you have with the investigator or staff nor standard of care you receive. 
 
Unforeseeable Risks 
In addition to the risks listed above, there may be risks which are currently unforeseen. 
 
Right of Investigator to Withdraw 
You may withdraw from the study at any time without penalty. Dr. Weeks or Dr. Smith 
can withdraw you without your approval.  Possible reasons for investigator withdrawal 
include significant worsening of depressive symptoms or evidence of intolerance to the 
treatment. 
 
Costs to Participants and Compensation 
There are no costs to you or any compensation for any of the procedures described 
above.  However, if you are assigned to the conventional ECT treatment, and you have 
medical insurance coverage, we will bill your provider for these treatment costs in the 
ordinary manner.   
 
New Information: 
Sometimes new information about the topic being studied becomes available during a 
research project. If this happens, your research doctor will tell you about it so you can 
decide whether or not to continue. 
 
Number of Participants 
We expect about 50 people will be in this study. 
  
Authorization for Use of Your Protected Health Information 
Signing this document means you allow us, the researchers in this study, and others 
working with us to use information about your health for this research study.  You can 
choose whether or not you will participate in this research study.  However, in order to 
participate you have to sign this consent and authorization form. 
This is the information we will use: 
• Name, address, and telephone number 
• Medical history including psychiatric symptoms, current and past medications or 
therapies 
• Information from the memory testing 
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• Information on changes in your psychiatric symptoms that occur over the testing 
period 
 
Others who will have access to your information for this research project are the 
University’s Institutional Review Board (the committee that oversees research studying 
people) and authorized members of the University of Utah workforce who need the 
information to perform their duties (for example: to provide treatment, to ensure 
integrity of the research, and for accounting or billing matters). 
If we share your information with anyone outside the University of Utah Health Sciences 
you will not be identified by name, social security number, address, telephone number, 
or any other information that would directly identify you, unless required by law. 
You may revoke this authorization.  This must be done in writing.  You must either give 
your revocation in person to the Principal Investigator or the Principal Investigator’s 
staff, or mail it to: Dr. Howard Weeks 501 Chipeta Way, Salt Lake City, Utah 84108.  If 
you revoke this authorization, we will not be able to collect new information about you, 
and you will be withdrawn from the research study.  However, we can continue to use 
information we have already started to use in our research, as needed to maintain the 
integrity of the research.  This authorization lasts until this study is finished. 
 
Consent 
I confirm that I have read and understand this consent and authorization document and 
have had the opportunity to ask questions.  I understand that my participation is 
voluntary and that I am free to withdraw at any time, without giving any reason, without 
my medical care or legal rights being affected.  I will be given a signed copy of the 
consent and authorization form to keep.  
 
I agree to participate in this research study and authorize you to use and disclose health 





________________________     ____________ 
Participant’s Signature    Date 
 
____________________________________________ 
Name of Person Obtaining Authorization and Consent 
 
 
______________________________________________               __________ 





Consent and Authorization Document 
Neurocognitive Effects of Bifrontal ECT Substudy 
Background 
You are being invited to take part in a research study conducted by researchers from the 
Departments of Psychiatry, Anesthesiology, Psychology and Neurology, University of 
Utah.  Before you decide if you want to participate, it is important for you to understand 
why the research is being done and what it will involve.  Please take time to read the 
following information carefully and discuss it with friends and relatives if you wish.  Ask 
us if there is anything that is not clear, or if you would like more information.  Take time 
to decide whether or not you want to volunteer to take part in this study. 
 
One of the standard medical treatments for moderate to severe clinical depression is 
Electroconvulsive Therapy (ECT), also known as “shock treatment”.  These ECT 
treatments are administered by physicians together with relaxant drugs and anesthetic 
medications and other therapeutic procedures as your physicians may in their judgment 
determine to be necessary or appropriate.  ECT treatments are usually repeated at 
intervals, usually every 2-3 days for about 2.5 to 3.5 weeks and about 8 total 
treatments.  In many cases, a series of ECT treatments leads to substantial 
improvement in symptoms of depression.  We are investigating the memory effects of 
ECT.  Your physician and the physicians involved in this study believe that you are an 
appropriate candidate for ECT.  
 
Study Procedure: 
You have been referred to have ECT based on the symptoms of your illness and your 
physician’s clinical judgment. This study will in no way change the standard practice of 
ECT and the delivery of your treatments. 
 
A series of memory and mental function tests will be performed prior to your 1st ECT and 
then be repeated 12-24 hours after the 8th treatment and 4 weeks after the 8th and final 
treatment.  Changes in severity of depressive symptoms will be assessed by a clinical 
interview before each of the 8 treatment sessions, as well as 12-24 hours after the last 
treatment session and at 4 weeks after the last treatment session.  Each set of testing 
will take approximately 1.5 hours. 
 
Risks:  The memory testing procedures involve minimal risk to participants.  You may 
become frustrated with the testing.  If you feel upset from this experience, you can tell 
the researcher, and they will tell you about resources available to help.   
Benefits: You will not receive any direct benefits from participating. However, if we find 
that there is no significant memory impairment with bifrontal ECT, this may be very 
helpful in the future to patients considering treatment with ECT. The information may 
also provide clues to the best memory sparing method of performing ECT, which may 
assist researchers in developing new treatments.  
 
Alternative Procedures 
If you do not want to take part in the study, you may choose to not participate in this 
study. This will in no way affect the treatment you receive from your medical providers. 
 
Confidentiality 
We will keep all research records that identify you private to the extent allowed by law. 
Records about you will be kept locked in filing cabinets or on computers protected with 
passwords. Only those who work with this study will be allowed access to your 
information. However, representatives from the Food and Drug Administration may 
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inspect and/or copy the records that identify you. Results of the study may be 
published; however, your name and other identifying information will be kept private.  
 
Person to Contact 
If you have questions, complaints or concerns about this study, or if you think you may 
have been injured from being in this study, you can contact Dr. Howard Weeks at 801-
583-2500. Dr. Weeks can be reached at this number 24 hours a day. 
 
Institutional Review Board 
Contact the Institutional Review Board (IRB) if you have questions regarding your rights 
as a research participant. Also, contact the IRB if you have questions, complaints or 
concerns which you do not feel you can discuss with the investigator. The University of 
Utah IRB may be reached by phone at (801) 581-3655 or by e-mail at irb@hsc.utah.edu. 
 
Research Participant Advocate:  You may also contact the Research Participant Advocate 
(RPA) by phone at (801) 581-3803 or by email at participant.advocate@hsc.utah.edu. 
 
Voluntary Participation 
It is up to you to decide whether or not to take part in this research.  If you do decide to 
take part you will be asked to sign this consent form. If you decide to take part you are 
still free to withdraw at any time and without giving a reason. This will not affect the 
relationship you have with the investigator or staff nor standard of care you receive. 
 
Costs to Participants and Compensation 
There are no costs to you or any compensation for any of the procedures described 
above.  However, if you are assigned to the conventional ECT treatment, and you have 
medical insurance coverage, we will bill your provider for these treatment costs in the 
ordinary manner.   
 
Authorization for Use of Your Protected Health Information 
Signing this document means you allow us, the researchers in this study, and others 
working with us to use information about your health for this research study.  You can 
choose whether or not you will participate in this research study.  However, in order to 
participate you have to sign this consent and authorization form. 
This is the information we will use: 
• Name, address, and telephone number 
• Medical history including psychiatric symptoms, current and past medications or 
therapies 
• Information from the memory testing 
• Information on changes in your psychiatric symptoms that occur over the testing 
period 
 
Others who will have access to your information for this research project are the 
University’s Institutional Review Board (the committee that oversees research studying 
people) and authorized members of the University of Utah workforce who need the 
information to perform their duties (for example: to provide treatment, to ensure 
integrity of the research, and for accounting or billing matters). 
If we share your information with anyone outside the University of Utah Health Sciences 
you will not be identified by name, social security number, address, telephone number, 
or any other information that would directly identify you, unless required by law. 
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You may revoke this authorization.  This must be done in writing.  You must either give 
your revocation in person to the Principal Investigator or the Principal Investigator’s 
staff, or mail it to: Dr. Howard Weeks 501 Chipeta Way, Salt Lake City, Utah 84108.  If 
you revoke this authorization, we will not be able to collect new information about you, 
and you will be withdrawn from the research study.  However, we can continue to use 
information we have already started to use in our research, as needed to maintain the 
integrity of the research.  This authorization lasts until this study is finished. 
 
Consent 
I confirm that I have read and understand this consent and authorization document and 
have had the opportunity to ask questions.  I understand that my participation is 
voluntary and that I am free to withdraw at any time, without giving any reason, without 
my medical care or legal rights being affected.  I will be given a signed copy of the 
consent and authorization form to keep.  
 
I agree to participate in this research study and authorize you to use and disclose health 





________________________     ____________ 




Name of Person Obtaining Authorization and Consent 
 
 
______________________________________________               __________ 



















On a scale of 1 to 7, with a rating of 1 reflecting no memory problems at all and 
7 indicating major or severe difficulties with memory, where would you rate your 
memory over the past 24 hours? (circle your response) 
 
 









































On a scale of 1 to 7, please rate how effective you feel your treatment was with 
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